

# (12) United States Patent

Van Der Werf et al.

(10) **Patent No.:** 

US 9,359,612 B2

(45) **Date of Patent:** 

\*Jun. 7, 2016

#### (54) PRODUCTION OF ITACONIC ACID

(71) Applicant: Nederlandse Organisatie voor

toegepast-natuurwetenschappelijk

Onderzoek TNO, Delft (NL)

Inventors: Maria Johanna Van Der Werf,

Wageningen (NL); Peter Jan Punt,

Houten (NL)

(73) Assignee: DUTCH DNA BIOTECH B.V., Zeist

(NL)

(\*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 152 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 14/147,747

(22)Filed: Jan. 6, 2014

**Prior Publication Data** (65)

> US 2014/0199754 A1 Jul. 17, 2014

#### Related U.S. Application Data

(62) Division of application No. 12/920,461, filed as application No. PCT/NL2009/050099 on Mar. 4, 2009, now Pat. No. 8,642,298.

#### (30)Foreign Application Priority Data

Mar. 5, 2008 (EP) ...... 08152332

(51) Int. Cl.

(2006.01)C12N 1/15 C12N 1/21 (2006.01)(2006.01)C07K 14/38 C12P 7/44 (2006.01)

C12N 15/80

(52) U.S. Cl. CPC ...... C12N 15/80 (2013.01); C07K 14/38 (2013.01); C12P 7/44 (2013.01)

(2006.01)

(58)Field of Classification Search

None

See application file for complete search history.

(56)References Cited

U.S. PATENT DOCUMENTS

6,171,831 B1 1/2001 Tsai et al.

FOREIGN PATENT DOCUMENTS

WO WO-00/37629 6/2000 WO WO-01/29073 4/2001 WO WO-2009/014437 1/2009

#### OTHER PUBLICATIONS

GenBank Accession No. CH476609 (Sep. 2006).\*

Database NCBI [Online], Accession No. XM\_001209274, Feb. 28,

Database UniProt [Online], Accession No. Q0C8L2, Oct. 17, 2006. Dwiarti et al., Journal of Bioscience and Bioengineering (2002) 94:29-33

International Search Report for PCT/NL2009/050099, mailed on Jul. 7, 2009, 4 pages.

Jaklitsch et al., Journal of General Microbiology (1991) 137(3):533-

Magnuson et al., Advances in Fungal Biotechnology for Industry,

Agriculture, and Medicine (2004) 1:307-340. Pel et al., Nature Biotechnology (2007) 25(2):221-231.

Sauer et al., Trends in Biotechnology (2008) 26(2):100-108.

Tamano et al., Fungal Genetics and Biology (2008) 45(2):139-151.

\* cited by examiner

Primary Examiner — Rebecca Prouty

(74) Attorney, Agent, or Firm — Morrison & Foerster LLP

#### (57)ABSTRACT

The invention relates to a nucleic acid sequence encoding an itaconate transporting Major Facilitator Superfamily Transporter (MFST) gene sequence and the protein encoded thereby. Preferably said sequence is the nucleic acid that comprises the sequence of ATEG\_09972.1 of Aspergillus terreus or homologues thereof. Overexpression of the protein enhances the production of itaconic acid in micro-organisms.

#### 11 Claims, 6 Drawing Sheets




Fig. 1




Fig. 2

### Fig. 3A Amino acid sequence of ATEG\_09972.1

MGHGDTESPNPTTTTEGSGQNEPEKKGRDIPLWRKCVITFVVSWMTLVVTFSSTCLLPAA PEIANEFDMTVETINISNAGVLVAMGYSSLIWGPMNKLVGRRTSYNLAISMLCACSAGTA AAINEEMFIAFRVLSGLTGTSFMVSGQTVLADIFEPVYRGTAVGFFMAGTLSGPAIGPCV GGVIVTFTSWRVIFWLQLGMSGLGLVLSLLFFPKIEGNSEKVSTAFKPTTLVTIISKFSP TDVLKQWVYPNVFLADLCCGLLAITQYSILTSARAIFNSRFHLTTALVSGLFYLAPGAGF LIGSLVGGKLSDRTVRRYIVKRGFRLPQDRLHSGLITLFAVLPAGTLIYGWTLQEDKGDM VVPIIAAFFAGWGLMGSFNCLNTYVAGLFHTLIYLFPLCTCPQ\*

### Fig. 3B cDNA sequence of ATEG\_09972.1

ATGGCCACGGTGACACTGAGTCCCCGAACCCAACGACGACGCACGGAAGGTAGCGGACAA AACGAGCCAGAGAAAAAGGGCCGTGATATTCCATTATGGAGAAAATGTGTCATTACGTTT GTTGTTAGTTGGATGACTCTAGTCGTTACTTTCTCCAGTACTTGTCTTCTTCCTGCCGCC CCTGAAATCGCGAATGAATTTGATATGACTGTCGAGACTATCAACATCTCCAATGCTGGT GTCCTAGTTGCCATGGGATATTCATCCCTCATATGGGGTCCCATGAACAAGTTAGTCGGC CGGCGGACATCATACAATCTGGCCATTTCAATGCTTTGTGCATGCTCCGCTGGAACGGCA ĠCGGĊGATAAACGAGĠAAATGTTCATAGCGTTCAGAGTGTTGAGCGGCTTAACCGGAACC TCGTTCATGGTCTCAGGCCAAACTGTTCTTGCAGATATCTTTGAGCCTGTTTACCGTGGG ACGGCGTAGGTTCTTCATGGCCGGGACTCTTTCTGGCCCTGCAATAGGCCCCTGCGTG GGAGGGGTCATCGTCACTTTCACGAGTTGGCGTGTTATCTTCTGGCTTCAACTAGGTATG AGCGGGCTGGGGCTCGTGCTTCTCTGCTATTTTTCCCGAAAATCGAAGGAAATTCTGAG AAGGTCTCAACGGCGTTTAAACCGACCACACTTGTCACAATCATATCGAAATTCTCCCCA CTCCTGGCAATCACGCAATATTCGATCCTGACTTCAGCTCGTGCCATATTCAACTCACGA TTTCATTTAACGACTGCCCTAGTATCGGGTCTCTTCTACCTCGCTCCAGGTGCCGGGTTC CTGATAGGCAGTCTCGTCGGCGGTAAACTTTCGGATCGCACCGTTCGGAGATACATAGTA AAGCGCGGATTCCGTCTCCCTCAGGATCGACTCCACAGCGGGCTCATCACATTGTTCGCC GTGCTGCCGCAGGAACGCTCATTTACGGGTGGACACTCCAAGAGGATAAGGGTGATATG OTAGTGCCCATAATCGCGGCGTTCTTCGCGGGCTGGGGGCTCATGGGCAGTTTTAACTGC CTGAACACTTACGTGGCTGGTTTGTTCCACACCCTCATTTATCTATTCCCTTTGTGTACA TGCCCACAATAA

## Fig. 3C Genomic DNA sequence of ATEG\_09972.1

ategeccacestgacacteaeteccceaacccaaceaceaceaceaaestaecegacaa AACGAGCCAGAGAAAAAGGGCCGTGATATTCCATTATGGAGAAAATGTGTCATTACGTTT GTTGTTAGTTGGATGACTCTAGTCGTTACTTTCTCCAGTACTTGTCTTCTTCCTGCCGCC CCTGAAATCGCGAATGAATTTGATATGACTGTCGAGACTATCAACATCTCCAATGCTGGT GTCCTAGTTGCCATGGGATATTCATCCCTCATATGGGGTCCCATGAACAAGTTAGTCGGC CGGCGGACATCATACAATCTGGCCATTTCAATGCTTTGTGCATGCTCCGCTGGAACGGCA GCGCGATAAACGAGGAAATGTTCATAGCGTTCAGAGTGTTGAGCGGCTTAACCGGAACC TCGTTCATGGTCTCAGGCCAAACTGTTCTTGCAGATATCTTTGAGCCTGTACGAATCACA CGCCCCCCCCCCATTGCGAAAACTAATCCGTTCGTGCGCAGGTTTACCGTGGGACG GCAAGTACTAGAACTCCCAACAGGAACTAATTGTATGAGCAGGCCCCTGCGTGGGAGGGG TCATCGTCACTTCACGAGTTGCCGTGTTATCTTCTGCCTTCAACTAGGTATGAGCGGGC TGGGGCTCGTGCTTCTCCGCTATTTTCCCGAAAATCGAAGGAAATTCTGAGAAGGTCT CAACGCCTTTAAACCGACCACACTTCTCACAATCATATCGAAATTCTCCCCAACGGATG TGCTCAAGCAGTGGGTGTATCCAAATGTCTTTCTTGCCGTAAGTGTCTGGGACATATACC CTCTGCATCTACTGGAAAACGAGATGCTCATGCCACAAATCAAAGGACTTATGCTGTGGC CTCCTGGCAATCAGGCAATATTCGATCCTGACTTCAGCTCGTGCCATATTCAACTCACGA TTTCATTAACGACTGCCCTAGTATCGGGTCTCTTCTACCTCGCTCCAGGTGCCGGGTTC CTEATAGGCAGTCTGGTGGCGGTAAACTTTCGGATCGCACGGTTCGGAGATACATAGTA AAGCGCGGATTCCCTCTCCCTCAGGATCGACTCCACAGCGGGTCATCACATTGTTCGCC GTGCTGCCCGCAGGAACGCTCATTTACGGGTGGACACTCCAAGAGGATAAGGGTGATATG GEAGTGCCCATAATCGCGGCGTTCTTCGCGGGCTTGGGGGCTCATGGGCAGTTTTAACTGC CTGAACACTTACGTGGCTGGTTTGTTCCACACCCTCATTTATCTATTCCCTTTGTCTACA TGCCCACAATAA

US 9,359,612 B2

### Fig. 4A Amino acid sequence of A. oryzae homologue

MGQPDLESQTPKTIDGATKEKEEKGSKVEKGYGLPLWRKCIILFVVSWMTLAVTFSSTSL LPATPEIAEBFNTTTETLNITNAGVLLAMGFSSLIWGPLNNLIGRRLSYNIAIFMLCVCS AATGAAVDLKMFTAFRVLSGLTGTSFMVSGQTILADIFEPVVRGTAVGFFMAGSVSGPAI GPCIGGLIVTFSSWRNIYWLQVGMTGFGLVLAILFVPEIKQESKEBPEEKEKRTVLSALR LPNPLRIFRQWVYPNVFFSDLTCGLLATFQYSLLTSARSIFNPRFHLTTALISGLFYLAP GAGFLIGSIIGGKLSDRTVRKYIVRRGFRLPQDRLNSGLVTLFAVLPVSALIYGWTLQEE KGGMVVPILAAFFAGWGLMGSFNTLNTYVAEALPHKRSEVIAGKYIIQYIFSAGSSALVV PIINAIGVGWTFTICVIFSIIGGLLTMATARWGLDMQQWVERKFRIHDKPGF\*

### Fig. 4B cDNA sequence of A. oryzae homologue

atgggtcaacccgatcttgaatctcaaacccccaaaactatagacggggccacgaaagag aaggaagagaaaggcagcaaagttgaaaagggttacgqtcthcctttgtggcggaaatgt atcatectetteqteqteaqttgqatqaetettqeeqttacetteteqaqeacatetett officetgeaaccccogagatcgccgaggagffcaacaccaccactgagacccfcaacafe aceaatgooggogttftgctggotatgggottctogtogottatotggggtooottgaat aatotqáttqqaaqaaqqototoqtataaoahtqcqatottoatqchotqtqtqttoq geagegaegggggetgeagtagaettgaagatgtttaeggettttegagtgttgageggt ttgacggggacgtcattcatggtatcgggacagaccattctggcggacatttttgaaccg gttgtocgtggtacagccgtgggattcttatggctggatctgtctccggtcctgcaatt gggcoolgtatoggaggcolcalcgtcaccttolccagctggcgcaatalctactggctd daagtoggcatgäcaggattoggcdtggttdtagccattdtdttcgtdcccgaaatdaaa caqqaatccaaaqaqqaacccqaaqaaaaqaqaqaqqacaqtactttccqcctacqc otottoaatocootoogaatottoagadaatgggtotatoodaacgtottottotoogac obaacctgeggtctcobogccapabbccaabactcgcbcctcacabccgccogcbcaate ttoaatoocogottocacotcacaacagoactcatotcoqqootottotacotoqoocoa ggaqctqqcttcctgatcqqcaqcatcatcqqcqqcaaactctccqaccqtaccqtccqc aagtacategteegtegegetteegabtgeeecaggategeeteaacteeggeetegte accetgttcgccgtgctacccgtttcggcgctgatctacggctggaccctgcaggaggag aagggtggtatggtegtgeegaltttggeggegttlilttgeaggltgggggettalgggg agtittaataotttgaacaottatgttgctgaggotctgoogcataagogctccgaagtc ategotggaaagtatatoatocagtatatottttoggoggggagtagtgogottgtggtg ccgattattaatgccattggggttgggtggacttttaccatttgtgtgatcttttccatc atoggtggtotgttaacgatggctaccgcgcgatggggtctggatatgcaacaatgggtg gagaggaagttccgcattcatgataaaccagggttttga

Fig. 4C Genomic DNA sequence of A. oryzae homologue

atgggtcaaccegatettgaatetcaaacccccaaaactatagacgggccacgaaagag aaggaagagagagcaaagttgaaaagggttacggtcttcctttgtggcggaaatgt atcatectettegtegteagttggatgaetettgeegttaeettetegageaeatetett ottectgcaaccccgagatcgccgaggagtteaacaccaccactgagaccctcaacatc accaatgccggcgttttgctgqctatgqqcttctcqtcgcttatctgqgqtcccttgaat aatctgattggaagaaggctotcgtataacattgcgatcttcatgctotgtgtgtttcg gcagcgacggggctgcagtagacttgaagatgtttacggcttttcgagtgttgagcggt ttgacggggacgtcattcatggtatcgggacagaccattctggcggacatttttgaaccg gtacttttttcgctacctttctctatgctcctgtgtactagtcagttaagtactaataatg googataggttgtccgtggtacagccgtgggattctttatggctggatctgtctccggtc ctgcaattgggcctgtatcggaggcctcatcgtcaccttctccagctggcgcaatatct actggctccaagtcggcatgacaggattcggcctggttctagccattctcttcgtccccg aaatcaaacaggaatccaaagaggaacccgaagaaaaagagaaggacagtactttccg ccctaogcctottcaatcocctccgaatcttcagacaatgggtctatcccaacgtcttct totoogtaagoootoottooactaactaaaactaaaccagacctcatcaactaacaatac ctccccaaaaaqqacctaacctqcqqtctcctcqccacattccaatactcqctcctcaca teegeegeteaatetteaateeeegetteeaeeteacaaeageaeteateteeggeete ttotacctogccccaggagctggottcctgatcggcagcatcatoggcggcaaactctcc gaccqtavcqtccqcaaqtacatcqtccqtcqcqqcttccqattqcccaggatcqccto aastooggootegtoaccotgttogcegtgctaccogttteggogctgatetacggetgg accetgeaggaggagaagggtggtatggtegtgeegattttggeggegttttttgeaggt tqqqqqcttatqqqcaqttttaatactttqaacacttatqttqctqqtqaqtttttccat a aggogtggaatggttgctaataatgatacagaggctctgccgcataagcgctccgaagtcategorggaaagtatatcatccagtatatctttttcggcggggagtagtgcgcttgtggt gccgattattaatgccattggggttgggtggacttttaccatttgtatgtttgaccttct tobbattebbettatbettattebbettatbettattebbettatbettatbebbatteb tgtgtaggtgtgatottttccatcatcggtggtctgttaacgatggctaccgcgcgatgg ggtctggatatgcaacaatgggtggagaggaagttccgcattcatgataaaccagggttt tiga

#### PRODUCTION OF ITACONIC ACID

# CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. Ser. No. 12/920,461 having a U.S. filing date of Nov. 29, 2010, now U.S. Patent 8,642,298, which is the national phase of PCT application PCT/NL2009/050099 having an international filing date of Mar. 4, 2009, which claims benefit of European patent application No. 08152332.6 filed Mar. 5, 2008. The contents of the above patent applications are incorporated by reference herein in their entirety.

# SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE

The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 20 313632010010SeqList.txt, date recorded: 3 Jan. 2014, size: 44,009 KB).

The invention relates to the field of microbial production, more specifically production of itaconic acid (itaconate), more specifically production of itaconate in micro-organ- 25 isms

Production and metabolism of itaconic acid in microbial cells has been studied extensively for several decades (Calam, C. T. et al., 1939, Thom. J. Biochem., 33:1488-1495; Bentley, R. and Thiessen, C. P., 1956, J. Biol. Chem. 226:673-720; 30 Cooper, R. A. and Kornberg, H. L., 1964, Biochem. J., 91:82-91; Bonnarme, P. et al., 1995, J. Bacteriol. 117:3573-3578; Dwiarti, L. et al., 2002, J. Biosci. Bioeng. 1:29-33), but the metabolic pathway for itaconic acid has not been unequivocally established (Wilke, Th. and Vorlop, K.-D., 2001, Appl. 35 Microbiol. Biotechnol. 56:289-295; Bonnarme, P. et al., 1995, J. Bacteriol. 177:3573-3578). Two complicating factors in this respect are that the biosynthesis route for itaconic acid is thought to occur both in the cytosol and the mitochondria (Jaklitsch, W. M. et al., 1991, J. Gen. Microbiol. Appl. 40 6:51-61) and that aconitase, the enzyme that interconverts citric acid into cis-aconitate, and vice versa, and other enzymes in the metabolic pathway have been found to be present in many isoforms in microbial cells.

Production of itaconic acid is now commercially achieved in *Aspergillus terreus*, which has physiological similarity to *A. niger* and *A. oryzae*. However, these latter two accumulate citric acid, due to the absence of cis-aconic acid decarboxylase (CAD) activity. Substrates used by these fungi include mono- and disaccharides, such as glucose, sucrose and fructose and starches, as they exist in forms that are degradable by the micro-organism, and molasses. Recently, it has been discovered that also glycerol is a useful substrate in itaconic acid production by *A. terreus* (U.S. Pat. No. 5,637,485).

The general scheme currently envisioned for itaconic acid 55 biosynthesis is given in FIG. 1, wherein clearly the existence of the biosynthetic route both in the cytosol and the mitochondria is depicted and the connection between these two compartments. At several points of this scheme possibilities exist to try to improve the existing commercial production of itaconic acid in micro-organisms.

#### SUMMARY OF THE INVENTION

The invention comprises a nucleic acid sequence encoding 65 an itaconate transporting Major Facilitator Superfamily Transporter (MFST) gene sequence (hereinafter "the itacon-

2

ate transporter"). Preferably said nucleic acid comprises the ATEG\_09972.1 sequence of *Aspergillus terreus* as depicted in FIG. 3B, or a nucleic acid that shares more than about 70%, preferably more than about 80%, preferably more than about 90% sequence identity with the sequence of ATEG\_09972.1 as depicted in FIG. 3b. In another embodiment, the invention comprises a protein encoded by said nucleic acid.

The invention further comprises a method for the production of itaconic acid. More specifically the invention relates to improved production of itaconic acid, comprising increasing the activity of a protein capable of transporting itaconate from the cytosol to the extracellular medium, in a suitable host cell. Preferably this is achieved by overexpression of a nucleic acid sequence encoding the protein of the invention. Preferably the said nucleic acid is derived from *Aspergillus* sp. such as, *Aspergillus terreus*, *Aspergillus niger*, *Aspergillus nidulans*, *Aspergillus oryzae* or *Aspergillus fuminagates*.

According to a further preferred embodiment, the said nucleic acid is expressed in a suitable vector, under control of its own or other promoters.

Also comprised in the invention is a method as described above, wherein the above described transport of itaconic acid is further increased by increasing the intracellular itaconic acid, using at least one but preferably a combination of the following methods:

1. overexpression of the gene coding for the enzyme CAD (see EP 07112895) which catabolises cis-aconitate to itaconic acid, preferably wherein said gene is encoded by the nucleic acid sequence of ATEG 09971.1; 2. overexpression of a gene coding for a protein capable of transporting di/tricarboxylate, preferably cis-aconitate, citrate or isocitrate, from the mitochondrion to the cytosol, more preferably the diacrboxylate transporter encoded by the nucleic acid sequence of ATEG 09970.1 (see EP 08151584); 3. a method as described above, wherein the activity of a regulator protein that comprises a zinc finger and a fungal specific transcription factor domain is modulated. Preferably said regulator protein is the protein encoded by the nucleic acid sequence of ATEG\_09969.1, located in the same gene cluster as the transporter of the invention. By using the above method 1 also organisms that do not or hardly produce itaconic acid like A. niger and A. oryzae due to the absence of endogenous cisaconic acid decarboxylase (CAD) activity can be used since expression of the CAD gene will cause itaconic acid produc-

Another embodiment of the present invention is formed by a host cell wherein a gene coding for an itaconate transporter is introduced. Preferably said gene comprises the nucleotide sequence of the invention encoding a transporter protein. A suitable host cell preferably is a host cell selected from filamentous fungi, yeasts and bacteria, more preferably from Escherichia coli, Aspergillus sp such as Aspergillus niger or Aspergillus terreus, citrate-producing hosts or lovastatin producing hosts. The invention further comprises a host cell as described above wherein the gene coding for a protein capable of transporting di/tricarboxylate, preferably cis-aconitate, citrate or isocitrate, from the mitochondrion to the cytosol, is co-expressed. The invention further comprises a host cell as described above, wherein the transported or produced cis-aconitate is catabolised to itaconic acid by overexpression of the gene encoding the enzyme CAD.

Further, the invention pertains to the use of the protein(s) transporting itaconate from the cytosol to the extracellular medium, for the production of itaconic acid by a suitable host cell. Also comprised in the invention is the use of said protein(s) combined with the proteins transporting di/tricarboxy-late over the mitochondrial membrane, the regulator protein

ATEG\_09969.2 and/or the use of the CAD enzyme, for the production of itaconic acid in a suitable host cell.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: Postulated biosynthesis route(s) for itaconic acid in *A. terreus*. 1, Citrate synthase; 2, Aconitase; 3, cis-aconitic acid decarboxylase (itaconate-forming); 4, cis-aconitic acid decarboxylase (citraconate-forming); 5, citraconate isomerase; 6, mitochondrial dicarboxylate-tricarboxylate <sup>10</sup> antiporter; 7, mitochondrial tricarboxylate transporter; 8, dicarboxylate transporter; 9, 2-methylcitrate dehydratase.

FIG. 2: Overview of *Aspergillus terreus* genome segment with the cluster of genes involved in production of itaconic acid and lovastatin ranging from ATEG 09961.1-ATEG 15 09975.1. The cluster contains the cis-aconitate decarboxylase (ATEG\_09971.1) and the mitochondrial tricarboxylate transporter (ATEG\_9970.1).

FIG. **3**A-C: Sequence of the *Aspergillus terreus* itaconate transporter: FIG. **3**A. protein sequence (SEQ ID NO:3), FIG. 20 **3**B. cDNA (SEQ ID NO:2), FIG. **3**C. genomic sequence (SEQ ID NO:1).

FIG. 4A-C: Sequence of the *Aspergillus oryzae* itaconate transporter: FIG. 4A. protein sequence (SEQ ID NO:6), FIG. 4B. cDNA (SEQ ID NO:5), FIG. 4C. genomic sequence <sup>25</sup> (SEQ ID NO:4).

#### DETAILED DESCRIPTION OF THE INVENTION

"Fungi" are herein defined as eukaryotic micro-organisms 30 and include all species of the subdivision Eumycotina (Alexopoulos, C. J., 1962, In: Introductory Mycology, John Wiley & Sons, Inc., New York). The term fungus thus includes both filamentous fungi and yeast. "Filamentous fungi" are herein defined as eukaryotic micro-organisms that include all fila- 35 mentous forms of the subdivision Eumycotina. These fungi are characterized by a vegetative mycelium composed of chitin, cellulose, and other complex polysaccharides. The filamentous fungi used in the present invention are morphologically, physiologically, and genetically distinct from 40 yeasts. Vegetative growth by filamentous fungi is by hyphal elongation and carbon catabolism of most filamentous fungi are obligately aerobic. "Yeasts" are herein defined as eukaryotic micro-organisms and include all species of the subdivision Eumycotina that predominantly grow in unicellular 45 form. Yeasts may either grow by budding of a unicellular thallus or may grow by fission of the organism.

The term "fungal", when referring to a protein or nucleic acid molecule thus means a protein or nucleic acid whose amino acid or nucleotide sequence, respectively, naturally 50 occurs in a fungus.

The term "gene", as used herein, refers to a nucleic acid sequence containing a template for a nucleic acid polymerase, in eukaryotes, RNA polymerase II. Genes are transcribed into mRNAs that are then translated into protein.

"Expression" refers to the transcription of a gene into structural RNA (rRNA, tRNA) or messenger RNA (mRNA) with subsequent translation into a protein.

The term "vector" as used herein, includes reference to an autosomal expression vector and to an integration vector used 60 for integration into the chromosome.

The term "expression vector" refers to a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest under the control of (i.e., operably linked to) additional nucleic acid segments that provide for its 65 transcription. Such additional segments may include promoter and terminator sequences, and may optionally include

4

one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both. In particular an expression vector comprises a nucleotide sequence that comprises in the 5' to 3' direction and operably linked: (a) a yeast-recognized transcription and translation initiation region, (b) a coding sequence for a polypeptide of interest, and (c) a yeast-recognized transcription and translation termination region. "Plasmid" refers to autonomously replicating extrachromosomal DNA which is not integrated into a microorganism's genome and is usually circular in nature.

An "integration vector" refers to a DNA molecule, linear or circular, that can be incorporated in a microorganism's genome and provides for stable inheritance of a gene encoding a polypeptide of interest. The integration vector generally comprises one or more segments comprising a gene sequence encoding a polypeptide of interest under the control of (i.e., operably linked to) additional nucleic acid segments that provide for its transcription. Such additional segments may include promoter and terminator sequences, and one or more segments that drive the incorporation of the gene of interest into the genome of the target cell, usually by the process of homologous recombination. Typically, the integration vector will be one which can be transferred into the host cell, but which has a replicon that is nonfunctional in that organism. Integration of the segment comprising the gene of interest may be selected if an appropriate marker is included within that segment.

"Transformation" and "transforming", as used herein, refer to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction, f-mating or electroporation. The exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host cell genome.

By "host cell" is meant a cell that contains a vector or recombinant nucleic acid molecule and supports the replication and/or expression of the vector or recombinant nucleic acid molecule. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, fungus, plant, insect, amphibian, or mammalian cells. Preferably, host cells are fungal cells.

Key in the biosynthetic pathway for itaconic acid is the
localisation of the various substrates. It is thought that production of itaconic acid mainly occurs in the cytosol (see FIG.

1). In many biochemical pathways, the end-product is inhibiting its own production to prevent excess end-product in the biological system. Excess end-product will not only lead to
loss of energy in an economical sense, it can also give rise to unwanted side effects such as toxicity. It is contemplated that by depleting the cell of itaconic acid the formation of new itaconic acid will continue without end-product inhibition, thus giving—in total—an increase yield of itaconic acid.

Additionally the present invention enables a more simple way of harvesting the itaconic acid due to its presence in the extracellular medium. This also enables continuous fermentation culture.

Also provided are functional homologues of the ATEG\_09972.1 sequences, that are 50% or more identical to the sequence of FIG. 3b, preferably 60% or more, more preferably 70% or more, more preferably 80% or more and most preferably 95% or more identical. Functional in the term functional homologues means that the homologous protein has an itaconic acid/itaconate transporter function i.e. is able to transport itaconate over the cell membrane.

The term "sequence identity," as used herein, is generally expressed as a percentage and refers to the percent of amino acid residues or nucleotides, as appropriate, that are identical as between two sequences when optimally aligned. For the purposes of this invention, sequence identity means the sequence identity determined using the well-known Basic Local Alignment Search Tool (BLAST), which is publicly available through the National Cancer Institute/National Institutes of Health (Bethesda, Md.) and has been described in printed publications (see, e.g., Altschul et al., J. MoI. Biol, 215(3), 403-10 (1990)). Preferred parameters for amino acid sequences comparison using BLASTP are gap open 11.0, gap extend 1, Blosum 62 matrix.

Every nucleic acid sequence herein that encodes a polypeptide also, by reference to the genetic code, describes every possible silent variation of the nucleic acid. The term "conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to 20 those nucleic acids which encode identical or conservatively modified variants of the amino acid sequences due to the degeneracy of the genetic code.

The term "degeneracy of the genetic code" refers to the fact that a large number of functionally identical nucleic acids 25 encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations" and represent one species of conservatively modified variation.

The present inventors have found a method for increasing the production of itaconic acid, by increasing the activity of the protein capable of transporting itaconate from the cytosol to the extracellular medium, leading to increased recovery of itaconic acid, produced by a suitable micro-organism. The protein is further defined as a protein capable of transporting itaconic acid.

Preferably, the itaconate transporter is the itaconate transporter of *Aspergillus terreus*, as is found in the itaconate/lovastatin gene cluster (see FIG. 2), which is represented by the nucleic acid sequence found in ATEG\_09972.1, which is disclosed in FIGS. 3b and 3c, for the cDNA and genomic 45 sequence, respectively.

Further example of an itaconate transporter that could also be used in the present invention is the homologous gene denominated BAE57135.1 from *A. oryzae*, as depicted in FIGS. 4a, 4b and 4c. The produced itaconic acid can be 50 recovered from the extracellular medium using methods know to a person skilled in the art and as described by Wilke et al. (Wilke, Th. and Vorlop, K.-D., 2001, Appl. Microbiol. Biotechnol. 56:289-295). One preferred way of increasing the activity of said protein(s) is by overexpression of a gene(s) 55 encoding said protein(s), preferably wherein said gene is ATEG\_09972.1.

Overexpression can be effected in several ways. It can be caused by transforming the micro-organism with a gene coding for the enzyme. Alternatively, other methods can be used 60 for effecting an increase in the activity of said enzyme. One possible way is to provide a stronger promoter in front of and regulating expression of the endogenous gene. This can be achieved by use of a strong heterologous promoter or by providing mutations in the endogenous promoter. An 65 increased activity of the enzyme can also be caused by removing possible inhibiting regulatory proteins, e.g. by inhibiting

6

the expression of such proteins. The person skilled in the art will know other ways of increasing the activity of the above mentioned enzyme.

The production of itaconic acid can be further optimised by combining the product secretion and recovery as described above, with overexpression of di/tricarboxylate transporters, capable of transporting, among others, cis-aconitate, citrate or isocitrate from the mitochondrion to the cytosol, preferably the gene encoded by the nucleic acid sequence of ATEG\_09970.1. These subsequent processes will lead to an increase in cis-aconitate in the cytosol, which can be further converted to itaconic acid, using overexpression of the gene encoding the enzyme CAD (EC 4.1.1.6). "CAD" is defined as the enzyme, or a nucleotide sequence encoding for the enzyme cis-aconitate decarboxylase (CAD), such as the enzyme encoded by the nucleic acid sequence of ATEG\_09971.1, this further comprises enzymes with similar activities (see EP07112895).

Even further optimisation of the present invention can be achieved by modulating the activity of the regulator protein that comprises a zinc finger and a fungal specific transcription factor domain as can be found on the gene cluster that also comprises ATEG\_09970, wherein this regulator protein is indicated as ATEG\_09969.1 (see FIG. 2).

The above described processes alone or in combination lead to a subsequent increase of itaconic acid (see FIG. 1). Another advantage of the invention is an improved method to recover the produced itaconic acid by increasing the release in the extracellular media. The combination of improved production and improved recovery leads to an increase in itaconic acid yield by a suitable host. The above described genes are preferably derived from Aspergillus sp. like, Aspergillus terreus, Aspergillus niger, Aspergillus nidulans, Aspergillus oryzae or Aspergillus fumigatus. However, it is also possible to derive the gene from other itaconate producing microorganisms such as Ustilago zeae, Ustilago maydis, Ustilago sp., Pseudozyma antarctica, Candida sp., Yarrowia lipolytica, and Rhodotorula sp.

In another aspect of the invention, micro-organisms overexpressing at least one but alternatively a combination of the
above mentioned nucleotide sequences, encoding at least a
protein capable of transporting itaconate from the cytosol to
the extracellular medium, are produced and used for
increased production of itaconic acid. More preferably
micro-organisms overexpressing a protein that transports itaconate combined with protein(s) that transport di/tricarboxylates from the mitochondrion to the cytosol and/or the CAD
enzyme are used to further improve the production of itaconic
acid.

Micro-organisms used in the invention are preferably micro-organisms that naturally produce itaconic acid. Preferably overexpression of the genes encoding the above described protein(s) and enzyme(s) is accomplished in filamentous fungi, yeasts and/or bacteria, such as, but not limited to Aspergillus sp., such as the fungi A. terreus, A. itaconicus and A. niger, Aspergillus nidulans, Aspergillus oryzae or Aspergillus fumigatus, Ustilago zeae, Ustilago maydis, Ustilago sp., Candida sp., Yarrowia lipolytica, Rhodotorula sp. and Pseudozyma antarctica, the bacterium E. coli and the yeast Saccharomyces cerevisiae. Especially preferred are heterologous citric acid producing organisms in which the substrates are available in the host organism.

Recently (see US 2004/0033570) it has also been established that the so-called D4B segment of *Aspergillus terreus*, which comprises the CAD gene is responsible for the synthesis of lovastatin (see FIG. 2). Thus, it is submitted that also these micro-organisms which are known to produce lovasta-

tin would be suitable candidates for the production of itaconic acid. Such micro-organisms include *Monascus* spp. (such as *M. ruber, M. purpureus, M. pilosus, M. vitreus* and *M. pubigerus*), *Penicillium* spp. (such as *P. citrinum, P. chrysogenum*), *Hypomyces* spp., *Doratomyces* spp. (such as *D. stemonitis*), 5 *Phoma* spp., *Eupenicillium* spp., *Gymnoascus* spp., *Pichia labacensis*, *Candida cariosilognicola*, *Paecilomyces virioti*, *Scopulariopsis brevicaulis* and *Trichoderma* spp. (such as *T. viride*).

Consequently also the CAD encoding part of the D4B 10 segment and the enzyme with CAD activity for which it codes from these above-mentioned lovastatin producing micro-organisms are deemed to be suitable for use in the present invention. It further is contemplated that a heterologous organism, which in nature does not or hardly produce itaconic 15 acid like *Aspergillus niger* or *Aspergillus oryzae* can be used when providing such an organism with a functional pathway for expression of itaconic acid, by overexpression of the above mentioned genes.

Recombinant host cells described above can be obtained 20 using methods known in the art for providing cells with recombinant nucleic acids. These include transformation, transconjugation, transfection or electroporation of a host cell with a suitable plasmid (also referred to as vector) comprising the nucleic acid construct of interest operationally coupled to 25 a promoter sequence to drive expression. Host cells of the invention are preferably transformed with a nucleic acid construct as further defined below and may comprise a single but preferably comprises multiple copies of the nucleic acid construct. The nucleic acid construct may be maintained episo- 30 mally and thus comprise a sequence for autonomous replication, such as an ARS sequence. Suitable episomal nucleic acid constructs may e.g. be based on the yeast 2µ or pKD1 (Fleer et al., 1991, Biotechnology 9: 968-975) plasmids. Preferably, however, the nucleic acid construct is integrated in one 35 or more copies into the genome of the host cell. Integration into the host cell's genome may occur at random by illegitimate recombination but preferably the nucleic acid construct is integrated into the host cell's genome by homologous recombination as is well known in the art of fungal molecular 40 genetics (see e.g. WO 90/14423, EP-A-0 481 008, EP-A-0 635 574 and U.S. Pat. No. 6,265,186) Most preferably for homologous recombination the ku70Δ/ku80Δ, techniques is used as described for instance in WO 02/052026 and Krappmann, 2007, Fungal Biol. Rev. 21:25-29).

Transformation of host cells with the nucleic acid constructs of the invention and additional genetic modification of the fungal host cells of the invention as described above may be carried out by methods well known in the art. Such methods are e.g. known from standard handbooks, such as Sambrook and Russel (2001) "Molecular Cloning: A Laboratory Manual (3rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, or F. Ausubel et al, eds., "Current protocols in molecular biology", Green Publishing and Wiley Interscience, New York (1987). Methods for transformation and genetic modification of fungal host cells are known from e.g. EP-A-0 635 574, WO 98/46772, WO 99/60102 and WO 00/37671.

In another aspect the invention relates to a nucleic acid construct comprising a nucleotide sequence encoding at least 60 an itaconate transporter as defined above and usable for transformation of a host cell as defined above. In the nucleic acid construct, the coding nucleotide sequence(s) preferably is/are operably linked to a promoter for control and initiation of transcription of the nucleotide sequence in a host cell as 65 defined below. The promoter preferably is capable of causing sufficient expression of the itaconate transporters transport-

8

ing itaconate from the cytosol to the extracellular medium and/or the di/tricarboxylate transporters transporting tricarboxylates from the mitochondrion and/or the CAD enzyme(s), described above, in the host cell. Promoters useful in the nucleic acid constructs of the invention include the promoter that in nature provides for expression of the coding genes. Further, both constitutive and inducible natural promoters as well as engineered promoters can be used. Promoters suitable to drive expression of the genes in the hosts of the invention include e.g. promoters from glycolytic genes (e.g. from a glyceraldehyde-3-phosphate dehydrogenase gene), ribosomal protein encoding gene promoters, alcohol dehydrogenase promoters (ADH1, ADH4, and the like), promoters from genes encoding amylo- or cellulolytic enzymes (glucoamylase, TAKA-amylase and cellobiohydrolase). Other promoters, both constitutive and inducible and enhancers or upstream activating sequences will be known to those of skill in the art. The promoters used in the nucleic acid constructs of the present invention may be modified, if desired, to affect their control characteristics. Preferably, the promoter used in the nucleic acid construct for expression of the genes is homologous to the host cell in which genes are expressed.

In the nucleic acid construct, the 3'-end of the coding nucleotide acid sequence(s) preferably is/are operably linked to a transcription terminator sequence. Preferably the terminator sequence is operable in a host cell of choice. In any case the choice of the terminator is not critical; it may e.g. be from any fungal gene, although terminators may sometimes work if from a non-fungal, eukaryotic, gene. The transcription termination sequence further preferably comprises a polyadenylation signal.

Optionally, a selectable marker may be present in the nucleic acid construct. As used herein, the term "marker" refers to a gene encoding a trait or a phenotype which permits the selection of, or the screening for, a host cell containing the marker. A variety of selectable marker genes are available for use in the transformation of fungi. Suitable markers include auxotrophic marker genes involved in amino acid or nucleotide metabolism, such as e.g. genes encoding ornithinetranscarbamylases (argB), orotidine-5'-decarboxylases (pyrG, URA3) or glutamine-amido-transferase indoleglycphosphoribosyl-anthranilate erol-phosphate-synthase isomerases (trpC), or involved in carbon or nitrogen metabolism, such e.g. niaD or facA, and antibiotic resistance markers such as genes providing resistance against phleomycin, bleomycin or neomycin (G418). Preferably, bidirectional selection markers are used for which both a positive and a negative genetic selection is possible. Examples of such bidirectional markers are the pyrG (URA3), facA and amdS genes. Due to their bidirectionality these markers can be deleted from transformed filamentous fungus while leaving the introduced recombinant DNA molecule in place, in order to obtain fungi that do not contain selectable markers. This essence of this MARKER GENE FREETM transformation technology is disclosed in EP-A-0 635 574, which is herein incorporated by reference. Of these selectable markers the use of dominant and bidirectional selectable markers such as acetamidase genes like the amdS genes of A. nidulans, A. niger and P. chrysogenum is most preferred. In addition to their bidirectionality these markers provide the advantage that they are dominant selectable markers that, the use of which does not require mutant (auxotrophic) strains, but which can be used directly in wild type strains.

Optional further elements that may be present in the nucleic acid constructs of the invention include, but are not limited to, one or more leader sequences, enhancers, integration factors, and/or reporter genes, intron sequences, cen-

tromers, telomers and/or matrix attachment (MAR) sequences. The nucleic acid constructs of the invention may further comprise a sequence for autonomous replication, such as an ARS sequence. Suitable episomal nucleic acid constructs may e.g. be based on the yeast 2µ or pkD1 (Fleer et al., 5 1991, Biotechnology 9: 968-975) plasmids. Alternatively the nucleic acid construct may comprise sequences for integration, preferably by homologous recombination (see e.g. WO98/46772). Such sequences may thus be sequences homologous to the target site for integration in the host cell's 10 genome. The nucleic acid constructs of the invention can be provided in a manner known per se, which generally involves techniques such as restricting and linking nucleic acids/ nucleic acid sequences, for which reference is made to the standard handbooks, such as Sambrook and Russel (2001) "Molecular Cloning: A Laboratory Manual (3rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, or F. Ausubel et al, eds., "Current protocols in molecular biology", Green Publishing and Wiley Interscience, New York (1987).

In a further aspect the invention relates to fermentation processes in which the transformed host cells of the invention are used for the conversion of a substrate into itaconic acid. A preferred fermentation process is an aerobic fermentation process. The fermentation process may either be a submerged 25 or a solid state fermentation process.

In a solid state fermentation process (sometimes referred to as semi-solid state fermentation) the transformed host cells are fermenting on a solid medium that provides anchorage points for the fungus in the absence of any freely flowing 30 substance. The amount of water in the solid medium can be any amount of water. For example, the solid medium could be almost dry, or it could be slushy. A person skilled in the art knows that the terms "solid state fermentation" and "semisolid state fermentation" are interchangeable. A wide variety of solid state fermentation devices have previously been described (for review see, Larroche et al., "Special Transformation Processes Using Fungal Spores and Immobilized Cells", Adv. Biochem. Eng. Biotech., (1997), Vol 55, pp. 179; Roussos et al., "Zymotis: A large Scale Solid State Fer- 40 menter", Applied Biochemistry and Biotechnology, (1993), Vol. 42, pp. 37-52; Smits et al., "Solid-State Fermentation-A Mini Review, 1998), Agro-Food-Industry Hi-Tech, March/ April, pp. 29-36). These devices fall within two categories, those categories being static systems and agitated systems. In 45 static systems, the solid media is stationary throughout the fermentation process. Examples of static systems used for solid state fermentation include flasks, petri dishes, trays, fixed bed columns, and ovens. Agitated systems provide a means for mixing the solid media during the fermentation 50 process. One example of an agitated system is a rotating drum (Larroche et al., supra). In a submerged fermentation process on the other hand, the transformed fungal host cells are fermenting while being submerged in a liquid medium, usually in a stirred tank fermenter as are well known in the art, 55 although also other types of fermenters such as e.g. airlifttype fermenters may also be applied (see e.g. U.S. Pat. No. 6,746,862).

Preferred in the invention is a submerged fermentation process, which is performed in a fed-batch or repeated (fed-) 60 batch mode. In a fed-batch fermentation there is a continuous input of feed containing a carbon source and/or other relevant nutrients in order to improve itaconic acid yields. The input of the feed can, for example, be at a constant rate or when the concentration of a specific substrate or fermentation parameter falls below some set point. In a repeated batch fermentation the culture is harvested at regular time-intervals by

10

stopping the fermentation and retrieving the produced product from the medium. Next to refreshing the medium often also part of the microbial culture is discarded, while the rest is used as a new inoculum for a following batch culture.

It is preferred to use a host cell that naturally would contain the enzymes/transporters of the itaconic acid pathway as depicted in FIG. 1, and the enzymes/transporters of the citric acid pathways in the cytosol and mitochondrion. However, if the host would lack one or more of these genes, they can be co-introduced with the above described enzymes and proteins. Such a co-introduction can be performed by placing the nucleotide sequence of such a gene on the same plasmid vector as the above described genes, or on a separate plasmid vector


Further, since the itaconic acid pathway is located partly in the cytosol and partly in the mitochondrion, it is contemplated that overexpression of the genes/enzymes in either or both of those compartments would be desirable. The person skilled in the art will know how to achieve overexpression in the cytosol or mitochondria by using the appropriate signal sequences.

#### **EXAMPLES**

#### Example 1

#### Construction of Micro-Array

An anonymous clone/EST-based array approach was taken according to the following scheme:



An *A. terreus* micro-array was made composed of a clone-based and an EST-based array.

Materials and Methods Construction Micro-Array Isolation of Chromosomal DNA from *A. Terreus* 

*A. terreus* was cultivated overnight in a shake flask in enriched minimal medium at 33° C. and 250 rpm. Enriched minimal medium (pH 5.5) is mineral medium (MM) supplemented with 0.5% yeast extract and 0.2% casamino acids. The composition of MM was: 0.07 M NaNO<sub>3</sub>, 7 mM KCl, 0.11 M KH<sub>2</sub>PO<sub>4</sub>, 2 mM MgSO<sub>4</sub>, and 1 m1/1 of trace elements (1000\* stock solution: 67 mM ZnSO<sub>4</sub>, 178 mM H<sub>3</sub>BO<sub>3</sub>, 25 mM MnCl<sub>2</sub>, 18 mM FeSO<sub>4</sub>, 7.1 mM CoCl<sub>2</sub>, 6.4 mM CuSO<sub>4</sub>, 6.2 mM Na<sub>2</sub>MoO<sub>4</sub>, 174 mM EDTA).

Mycelium was harvested after 22 hours and frozen in liquid nitrogen. Chromosomal DNA was isolated from 4.5 g mycelium following the protocol described below.

Grind 0.5-1.0 g mycelium under liquid nitrogen using the membrane disrupter.

Place polypropylene tubes (Greiner) with 1.5 ml watersaturated phenol, 1 ml TNS, 1 ml PAS and 0.5 ml 5×RNB in a water bath at 55° C., add the still frozen 5 mycelium to the tubes and vortex every 20 seconds for totally 2-4 minutes.

TNS: triisopropyl naphthalene sulphonic acid, 20 mg/ml in water, freshly prepared

PAS: 4 aminosalisylic acid, 120 mg/ml in water, freshly

5xRNB: 60.55 g Tris, 36.52 g NaCl, 47.55 g EGTA in 500 ml water (pH=8.5)

Add 1 ml sevag (24:1 chloroform:isoamyl alcohol) and 15 vortex with intervals for another 1-2 minutes.

Spin for 10 min. in the tabletop centrifuge at 4° C. at maximum velocity.

Extract the water-phase once again with phenol-sevag and twice with sevag. GENTLY, AVOID SHEAR- 20 ING!

Precipitate the DNA with 2 volumes ethanol. Spin directly for 10 min. in the tabletop centrifuge.

Drain the tube, dry it with Kleenex and resuspend the pellet in 500 µl Tris/EDTA. Transfer to a microvial. 25

Extract with phenol-sevag until interface stays clean. Then extract once with sevag.

Precipitate with 2 volumes ice-cold ethanol, spin down and resuspend the pellet in 100-200 µl TE with 50 μg/ml RNase.

Construction of Clone-Based gDNA Library

The gDNA library was prepared as follows:

Chromosomal A. terreus DNA was sheared into fragments of size 1.5-2.5 kb

The sheared DNA was subsequently size fractionated, endrepaired (Lucigen), and ligated into blunt-end pSMART-HC-Amp vectors (Lucigen).

The ligated constructs were transformed into E. coli DH

Colony PCR was performed on 96 transformants to check that >90% of the inserts had the correct size

Sequence analysis (short run) was performed on 20 clones to confirm their diversity and fungal origin

Colony picking of 20,000 amp-resistant colonies was car- 45 ried out into 96-well microtiter plates containing TY medium+100 μg/ml ampicillin

The 20.000 clones were replicated into 96-well microtiter plates. The ordered libraries are stored as glycerol stocks at -80° C.

Generation of mRNA for cDNA Library Construction

Precultures: A. terreus spores (106-107/ml) were inoculated into 100 ml B medium (2 g/l NH4NO3; 1 g/l MgSo4\*7H2O; 0.008 g/l ZnSO4\*7H2O; 0.015 g/l CuSO4\*5H2O; 1.5 ppm FeSO4\*5H2O; 0.08 g/l KH2PO4; 55 10 g/l CaCl2\*2H2O, set to pH 3.1 with HCl) containing 20 g/l glucose, and incubated for 24-48 hours at 37° C. at 250 rpm. Production cultures (B medium containing 100 g/l glucose) were inoculated 1/10 (v/v) for 2-days cultivations and 1/25 (v/v) for 3-day cultivations. After 2-3 days cultivation myce- 60 lium was harvested, filtered over miracloth, washed with 0.2 M sodium phosphate buffer (pH 6.5), frozen in liquid nitrogen and stored at -80° C.

Isolation of mRNA from A. terreus

grind mycelium with mortar and pestle under liquid nitro- 65 gen; add 100 μl β-mercaptoethanol before grinding to inactivate RNAse

12

transfer powder to cooled plastic tube (1.0 g per tube); keep mycelium frozen

add 4 ml TRIzol® and vortex till homogenous

add 0.4 ml chloroform and vortex

centrifuge for 20-30 min. at 3700 rpm, 4° C.

transfer supernatant to Eppendorf<sup>TM</sup> tubes (1.2 ml per tube) add 0.7 ml per 1.2 ml supernatant

centrifuge in Eppendorf™ centrifuge for 15 min. at 14.000 rpm, 4° C.

wash pellet with 1 ml 70% ethanol

centrifuge 5 min., 14.000 rpm, 4° C.

air-dry pellet and resuspend in 0.2 ml water

store RNA samples at -80° C.

Construction of cDNA Library

The cDNA library was prepared as follows:

The RNA was run on gel to determine the quality of the

polyT-primed cDNA was prepared from the total RNA provided (RT-PCR reaction using superscript and dT primers

The cDNA was size fractionated to give fragments of size 1.0-1.5 kb

The fragments were end-repaired (Lucigen), and ligated into blunt-end pSMART-HC-kan vectors (Lucigen).

Restriction analysis of 96 clones was performed to check the insert size and the % of transformants which had the correct insert size

Sequence analysis (short run) of 20 clones was performed to confirm diversity and fungal origin

5,000 kanamycin-resistant colonies were picked into microtiter plates

The 5000 cDNA clones were replicated into 96-well microtiter plates. The ordered libraries were stored as glycerol stocks at -80° C.

Construction of the A. Terreus Clone-Based Array

PCR fragments were generated from the different clones from the gDNA (20,000 clones) and cDNA (5,000 clones) library by mass 96 well PCR (50 µl/well, Lucigen SMART-SR1/SL1 primers with 5'-C6-aminolinkers, SuperTaq and buffer from HT Biotech. Ltd, dNTP's (Roche 11 969 064 001), pintool dipped template from grown colony plates).

All above PCR products were purified by 96 well precipitation (isopropanol and 96% ethanol wash), speedvac dried, dissolved in 15 µl 3xSSC/well and spotted with quill pins (Telechem SMP3) on CSS100 silylated aldehyde glass slides (Telechem, USA) using a SDDC2 Eurogridder (ESI, Canada). During spotting, aminolinkers of PCR products will covalently link with aldehyde groups of the coated slides.

gDNA and cDNA PCR products were spotted on two separate slides (slide a: 1st 10,000 gDNA's+5000 cDNA's; slide b: 2nd 10,000 gDNA's+same 5000 cDNA's).

For the clone-based array a genomic library was constructed. A total of 20,000 clones containing chromosomal fragments was generated, 90% of which had an average insert size of 1.5-2.5 kb. This resulted in a full genome coverage of 64% (Akopyants et al., 2001).

For the EST-based array a cDNA library of in total 5000 cDNA clones was constructed, 70% of which had an average insert size of 1.0-1.5 kb. This so-called EST-based approach has the advantage that it will be enriched for the genes expressed under the selected (itaconic acid producing) conditions. Moreover, in the EST-based approach per clone (and thus spot) only a single gene is represented in eukaryotes.

The complete micro-array, thus consisting of 20,000 genomic DNA clones and 5,000 cDNA clones was composed of an A and a B glass slide. Both slides contained the same 5,000 cDNA spots. The A and B slide each contained 10,000 of the gDNA spots.

#### Example 2

# Generation of the Different RNA Samples by Fermentation

Materials and Methods Fermentation and mRNA Isolation Fermentation conditions of *A. terreus* 

5-Liter controlled batch fermentations were performed in a New Brunswick Scientific Bioflow 3000 fermentors. The following conditions were used unless stated otherwise: 37° C.

pH start 3.5 set point 2.3 DO set points Day 1: 75% Day 2, 3, 4: 50%

Subsequent days: 25%

Preculture: 100 ml of the same medium as used in the fermentation medium (10<sup>7</sup> spores/ml) in 500 ml Erlenmeyer flask with baffles, overnight, 37° C., 150 rpm

pH control: 4M KOH (Base), 1.5 M H<sub>3</sub> PO<sub>4</sub> (Acid)

Antifoam: Struktol (Schill & Seilacher)

Fermentation Medium Compositions:

Per litre: 2.36 g of NH<sub>4</sub>SO<sub>4</sub>, 0.11 g of KH<sub>2</sub>PO<sub>4</sub>, 2.08 g of MgSO<sub>4</sub>\*7H<sub>2</sub>O, 0.13 g of CaCl<sub>2</sub>\*2H<sub>2</sub>O, 0.074 g of NaCl, 0.2 mg of CuSO<sub>4</sub>\*5H<sub>2</sub>O, 5.5 mg of Fe(III)SO<sub>4</sub>\*7H<sub>2</sub>O, 0.7 mg of MnCl<sub>2</sub>\*4H<sub>2</sub>O and 1.3 mg of ZnSO<sub>4</sub>\*7H<sub>2</sub>O and 100 g of  $_{30}$  glucose as a carbon source.

All media were prepared in demineralised water. Isolation of mRNA from *A. terreus* 

See mRNA isolation protocol described in Example 1 Determination of the Itaconate Concentration by HPLC

 $5~\mu l$  of a 10-times diluted supernatant sample (split ratio 1:3) was separated using a Waters 2695 Separations module on a reversed-phase Develosil 3  $\mu m$  RP-Aqueous C30 140A column (150×3 mm) (Phenomenex p/n CH0-6001) at 25° C. using the solvent gradient profile (flow rate was 0.4 ml/min) shown in Table 1.

**14** TABLE 1

		Solvent gradient of the RP-UV r	nethod.	_
5	Time (min)	A (20 mM NaH <sub>2</sub> PO <sub>4</sub> pH 2.25) (%)	B (Acetonitril) (%)	
	0	100	0	_
	10	100	0	
	15	95	5	
10	20	95	5	
	21	100	0	
	30	100	0	

Compounds were detected by UV at 210 nm using a Waters 2487 Dual wavelength Absorbance detector (Milford, Mass., USA).

Itaconate Productivity

Itaconate productivity at a certain time point was calculated as the slope of the regression line between that particular time point and the time points right before and after that time point. To this end of 6-10 supernatant samples of the different fermentations, the itaconate concentrations were determined by HPLC.

For the transcriptomics approach it is essential to have RNA samples from fermentations that result in the production of different amounts of itaconate. Therefore a literature survey was performed in order to identify medium components and/or physicochemical conditions that affect the amount of itaconate produced by *A. terreus*. Although many conflicting reports were found regarding the effect that a specific parameter has on itaconic acid production, 4 key overall parameters were identified from this literature survey, i.e. (i) carbon source, (ii) pH, (iii) trace element (i.e. Mn) concentration and (iv) oxygen tension. Fermentations with *A. terreus* varying principally in these four parameters were performed on a mineral salts medium to ensure that the elemental limitations required for itaconate production would be achieved. Table 2 presents an overview of the fermentations performed in this study.

TABLE 2

Overview of the fermentations performed in order to generate RNA samples for transcriptome analysis. The reference fermentation is on 100 g/l glucose, dO2, day 1, 75%; day 2-4, 50%, day 5 and further 25%, pH start 3.5, set point at 2.3.

Fermentation run	Fermentation	Environmental condition	Max. Itaconic acid (g/l)	Max. Biomass (gDWT/kg)
First Run	1	Glucose (100 g/l) (control)	16.1	12.7
	2	Fructose as C-source	8.84	13.7
	3	Maltose as C-source	13.9	12.1
Second run	4	Glucose (100 g/l) pH start	25.8	11.6
		3.5, set point 2.3 (control)		
	5	pH set 3.5	8.7	16.5
	6	pH start 3.5 no set point	30.6	8.7
Third run	7	Low glucose (30 g/l)	11.1	6.7
	8	O <sub>2</sub> set point 25%	47.2	12.0
	9	5* higher Mn	20.3	13.8
Fourth run	10	Glucose (100 g/l) (control)	26.9	17.9
	11	pH set 4.5	0.1	20.4
	12	O <sub>2</sub> set point 10%	52.9	10.6

As shown in Table 2, a considerable variation in the amount of itaconate is produced in this set of fermentations, ranging from almost no itaconate (fermentation #11; pH 4.5) to about 50 g/l itaconate (#8 and #12;  $O_2$  set point 25% and 10% respectively).

Of each fermentation 2 to 5 samples were harvested for isolation of mRNA.

From in total 23 fermentation samples mRNA could be isolated. Of 7 samples, mRNA was isolated twice independently. It proved to be especially difficult (impossible) to extract RNA from the samples taken in the stationary phase. A number of samples showed partial degradation of the RNA. Although no mRNA could be isolated from the samples from fermentations #6 and #12, the remaining samples still covered the complete range of itaconate production (Table 3).

TABLE 3

List of 30 mRNA samples from various fermentation conditions that were used for transcriptome analysis. The samples marked with asterisk were the samples used for the differential expression data analysis.

Sam- ple No.	Fer- mentation condition	RNA id	EFT (hours)	Itaconic acid (g/l)	Itaconic acid Productivity	
R3	gluc100	1.3.a	50.3	14.6	0.117	ok
R4	gluc100	1.4.a	74.8	16.1	0.060	ok
R5	fruc100	2.3.a	50.3	8.2	0.082	ok
R6	fruc100	2.3.b	50.3	8.2	0.082	ok
R7	fruc100	2.4.a	75.05	8.6	-0.013	ok
R8	malt100	3.3.a	50.3	7	0.355	ok
R9	malt100	3.4.a	75	12.1	0.220	ok
R10	pH-i3.5	4.3.a	53.25	25.8	0.146	part degr
R11	pH-i3.5	4.3.b	53.25	25.8	0.146	part degr
R12	pH-i3.5	4.4.a	73	24	-0.153*	ok
R13	pH-c3.5	5.3.a	53.5	7.5	-0.042	ok
R14	pH-c3.5	5.3.b	53.5	7.5	-0.042	ok
R15	pH-c3.5	5.4.a	73.25	7.9	0.035	ok
R16	gluc30	7.2.a	30.25	9	0.317	ok
R1	gluc30	7.3.a	43.5	10	0.030	ok
R17	gluc30	7.3.a	43.5	10	0.030	ok
R18	O2s25%	8.2.a	30.5	36*	0.824*	ok
R19	O2s25%	8.4.a	78.25	46	0.029	part degr
R20	5xMn	9.2.a	30.75	1	0.194	ok
R21	5xMn	9.2.b	30.75	1	0.194	ok
R22	5xMn	9.3.a	53.5	10	0.496	part degr
R23	5xMn	9.3.b	53.5	10	0.496	part degr
R24	5xMn	9.4.a	78.5	19	0.189	part degr
R25	5xMn	9.4.b	78.5	19	0.189	part degr
R26	5xMn	9.5.a	93.25	20	0.106	ok
R2	Gluc100	10.3.a	51.5	14.7	0.256	ok
R27	Gluc100	10.3.a	51.5	14.7	0.256	ok
R28	Gluc100	10.4.a	74	19.5	0.085	ok
R29	Gluc100	10.5.a	100.4	22	0.177	part degr
R30	Gluc100	10.5.b	100.4	22	0.177	part degr
R31	pH4.5	11.3.a	51.5	0.04*	-0.001	ok
R32	pH4.5	11.4.a	74	0.05*	0.003	ok

#### Example 3

Transcriptome Analysis, Data Analysis of the Array Data

 $\label{thm:main} \mbox{Materials and Methods Transcriptome Analysis, Data Normalization and Data Analysis}$ 

Labeling of RNA and gDNA

Total RNA's (5  $\mu$ g/30  $\mu$ l reaction), isolated from various *A.* 65 terreus cultures (strain NRRL 1960, BASF) with differential itaconate production, were labelled with amino-allyl-dUTP

16

(0.75  $\mu$ M aa-dUTP final conc., Sigma A0410), using 3  $\mu$ l 50  $\mu$ M oligo p(dT)<sub>1.5</sub> primer (La Roche, 814270), unlabelled dNTP's (added to 1.25  $\mu$ M final conc. for each dNTP), 2  $\mu$ l Superscript II Reverse Transcriptase and buffer (Life Technologies, 10297-018: primer annealing 10 min 70° C., transcriptase 180 min 42°). After RNA hydrolysis (3  $\mu$ l 2.5M NaOH, 30 min 37°, 3  $\mu$ l 2.5 M HAc) the aa-dUTP labelled cDNA was directly purified (below).

As a reference for correcting slide differences (spotting, labeling-, hybridization- and scan efficiency), gDNA (0.5 μg/reaction) of *Aspergillus terreus* (strain NRRL 1960, BASF) was labelled with aa-dUTP, using dNTP's (conc. as above), Klenov-DNA Polymerase and buffer (Bioprime kit, Invitrogen 18094-011: primer annealing 5 min 96° C., polymerase 90 min 37°).

The aa-dUTP-labelled cDNA or gDNA was purified (QIAquick column, Qiagen 28106), speedvac dried, dissolved (4.5 µl 0.1 M Na<sub>2</sub>CO<sub>3</sub>), coupled with 4.5 µl Cy5—NHS-ester for cDNA, or 4.5 µl Cy3-NHS-ester for gDNA (Amersham/GE-Healthcare PA25001 or PA23001 respectively, each in 73 µl DMSO) for 60 min at 20° C., diluted with 10 µl of water, and again purified on Autoseq G50 columns (GE-Healthcare 27-5340).

Array Blocking, (Pre)Hybridization and Image Analysis

Before hybridization with the array produced as described above, slides were blocked (removal surplus of spotted PCR products and blocking of free aldehyde groups) by 3× quickly washing (20° C.) with Prehyb buffer and 45 min incubation (42° C.) in PreHyb buffer (5×SSC, 1% BSA, 0.1% SDS). After 4 washes in water, spotted PCR products were denatured by dipping the slides 5 sec in boiling water and drying them with a N<sub>2</sub>-gas-pistol.

The Cy5- and Cy3-labelled sample were combined, 8 µl 25 μg/μl yeast tRNA (Invitrogen, 15401-029) and 4 μl 5 μg/μl poly-dA/dT (Amersham 27-7860) were added, the mixture was speed vac dried, dissolved in 160 µl Easyhyb buffer (Roche, 1 796 895), denatured (2 min, 96° C.), cooled to 50° C., applied on a pair of prehybridised slides (a+b, 80 µl/slide) prewarmed at 50° C., covered with a cover slide (Hybri slibs, Mol. Probes. H-18201) and incubated overnight at 42° C. in a 45 humidified hybridization chamber (Corning 2551). Slides were washed (pair a+b in one 50 ml tube, 1× in 1×SSC/0.1% SDS 37° C., 1× in 0.5×SSC 37° C., 2× in 0.2×SSC 20° C.) and dried with N<sub>2</sub>-gas. All pre-hybridisation buffers were 0.45 μm filtered to reduce dust noise. Slide images of Cy5- and Cy3fluorescence intensity (ScanArray Express Scanner & Software, Packard Biosc.) were analysed (Imagene 5.6 Software, Biodiscovery) to obtain for each spot signal- and local background value (medians) for the hybridized Cy5-RNA and 55 Cy3-reference gDNA. These values were used for further data analysis.

Array Data Normalization

Before normalization, all low abundant spots having a Signal/Background below 1.5 were removed. Data were normalized using a total cDNA signal correction. For each slide and each spot, the difference between signal and background was calculated for Cy5 and Cy3. Per slide, the sum of the differences was taken for Cy5 and Cy3, and the ratio between these two was used as normalization factor for that particular slide. All spots (chromosomal and genomic) were normalised using this total cDNA signal.

Data Analysis of the Transcriptomics Data by Multivariate Regression Analysis

Scaling

Data were range scaled  $(x-\bar{x})/(x_{max}-x_{min})$ ] (van den Berg et al., 2006, BMC Genomics 7:142) in the statistical analysis. Mathematically, range-scaling means that every element of column i is divided by the range of column i. The range of column i is the difference between the maximum and minimum value of all elements of column i. Subsequently, the scaled dataset is mean-centered. Mathematically, mean-centering means that adding up the values of the individual elements of column i of a data matrix results in zero for column i. This is achieved by subtracting the mean of column i from all values of the individual elements of column i.

PLS Analysis

PLS analysis (Geladi and Kowalski, 1986) was performed in the Matlab environment using the PLS Toolbox (version 3.5.4, 2006; Eigenvector Research, Manson, Wash.).

It is possible that transcripts that show a lot of variation disturb the performance of the PLS model. Therefore, the model was optimized using a jack-knife approach. A model was build leaving out 10% of the samples, which was repeated until all samples were left out once. For each transcript, the relative standard deviation (RSD) was calculated and transcripts which had an RSD>50% were left out to build a second PLS model.

Validation of the Results

A double cross-validation procedure was used to validate the PLS model. In short, two loops are defined: an inner loop and an outer loop. In the innerloop 90% of the data is used to find an optimal PLS model. In the outerloop a prediction is made for the remaining 10% of the data based on the innerloop PLS model. This is repeated until all samples are left out once (so in this case 10 times). Goal of the DCV is to get an independent estimate of the prediction error. The  $R^2$  was calculated to determine how good the original productivity or titer was predicted by the model. The closer the  $R^2$  gets to 1, the better the model.

Sequence Analysis of Spots Selected after Transcriptomics Approach

The relevant clones were selected from the glycerol stocks of the ordered libraries (gDNA and cDNA library respectively) and cultivated in 96-well microtiter plates. The sequences of the inserts from both the 3' and the 5' end were determined by High Throughput (HT) sequencing service.

All RNA samples were labelled with Cy5. Hybridisations were performed with all 30 RNA samples, using Cy3-labeled chromosomal DNA of *A. terreus* as the reference.

The raw transcriptomics data were shown to be of high 55 quality, based on visual inspection of the arrays after fluorescence scanning Notably, also the hybridization with the partially degraded RNA samples gave good results.

The normalized data were subsequently combined. As the *A. terreus* array consisted out of two slides, different strategies of combining the data from the two slides were pursued, making use of the fact that the cDNA clones are present on both the A and B slide:

SET 1=mean expression signal of the cDNA clones on  $_6$  slide A and B, take only those spots that give a signal on both the A and B slide

18

SET 2=use only the signal of the cDNA spots on the A slide. Spots with a Signal/Background below 1.5 were removed.

SET 3=use only the signal of the cDNA spots on the B slide. Spots with a Signal/Background below 1.5 were removed.

SET 4=Combinean cDNA data of both the A and B slide; i. If both measurement values were zero the combined value was zero:

- ii. If both measurements values were both non-zero, the combined value was equal to the average of the two measurement values;
- iii. If one of the two measurement values was zero and the other measurement value was non-zero, the combined value was equal to the non-zero measurement value.

SET 5=SET 1+normalized gDNA spots using the normalization factor calculated based on the cDNA clones.

The most relevant spots were subsequently identified by multivariate regression analysis. Multivariate data analysis (MVDA) tools seem very well suited to prioritize leads from functional genomics datasets. These tools take into account the inherent interdependency of biomolecules. These tools allow the identification of the specific genes that are the most important for a specific phenotype by determining the strength of the correlation of the expression of every gene with the biological question under study. Especially the regression tool partial least squares (PLS) holds great promise. Principally, the application of PLS results in a model (equation) that predicts a quantifiable phenotype of interest (e.g. itaconic acid titer, P) in terms of the transcripts (A, B, C, . . . ) expressed in *A. terreus*;

 $P = b_1 A + b_2 B + b_3 C + \dots$ 

By subsequently ordering the transcripts based on the absolute value of the regression values (i.e.  $b_1, b_2, b_3, \ldots$ ) transcripts are identified that contribute the most to itaconate production.

PLS models with both the itaconate titers of the different samples and the itaconate productivity of the different samples were built using these different combined data sets. Moreover, not only linear models but also logarithmic models were built using the log of the itaconate titer (Table 4). Of these, only the (linear) itaconate titer models were reasonably good models as judged by the (double) cross validation results and the stability of these models (i.e. R<sup>2</sup> double cross validation~0.4-0.5) (Table 4). The results of the other PLS models were very poor, and these models were not pursued.

TABLE 4

X (data set)	Y (Phenotype)	R <sup>2</sup> double cross validation PLS model
SET 1	Productivity	0.10
	Titer	0.51
	Log(titer)	0.05
SET 2	Productivity	0.13
	Titer	0.41
	Log(titer)	0.18
SET 3	Productivity	0.08
	Titer	0.45
	Log(titer)	0.06

		R <sup>2</sup> double cross validation
X (data set)	Y (Phenotype)	PLS model
SET 4	Productivity	0.07
	Titer	0.40
	Log(titer)	0.12
SET 5	Productivity	0.08
	Titer	0.38
	Log(titer)	0.05

Moreover, a second PLS model was built with the titer as the Y-variable, using only the transcripts whose regression value had an RSD <50% (as determined based on jack-knifing) in the first PLS model. This were, in general, only some 10-20% of the spots of the complete data set.

'Top 20'-ies of the combined data data sets analyzed by PLS using the itaconic acid titer as the phenotype were generated. These 'top-20'-ies were combined, and unique spots were identified (Table 5 and 6). In total 102 of the most relevant spots obtained after PLS analyses (based on 10 models; 5 data sets, 2 PLS models per data set) were selected for sequencing.

Of the selected spots, >92% were spots belonging to cDNA clones. However, also four of the 5 combined data sets contained only cDNA clones (see above).

Following sequence analysis of the 102 selected spots, the genes present on these inserts were identified by performing a homology search using BLAST based on the draft version of the A. terreus genome sequence as available from the BROAD institute (located on the World Wide Web at: broad.mit.edu/annotation/fgi/).

As different combined data sets/'top 20'-ies were generated, the overall ranking of the transcripts, as reported in Table 5 was based on:

(i) The frequency of occurrence of an individual spot in the top 20 of the different combined data sets analyzed

20

(ii) The sum of the overall rank of a spot in the different 'top 20'-ies of the different combined data sets.

Table 5 shows the results of the genes identified on the 20 highest overall ranking spots identified by PLS analysis based

TABLE 5

10	Overall Top 20 PLS analysis - itaconic acid titer.									
	Rank	Clone ID	Gene locus	Gene name						
_	1	AsTeR010H08								
15	2	AsTeR037H12								
	3	AsTeR053F06								
	4	AsTeR037C07								
	5	AsTeR007H08								
	6	AsTeR048G12								
20	7	AsTeR023B07								
	8	AsTeR033F08								
	9	AsTeR035E10								
	10	AsTeR033A04								
	11	AsTeR029F07								
25	12	AsTeR045A05								
	13	AsTeR010H12								
	14	AsTeR041C10								
	15	AsTeR030D01	ATEG_09972.1	Predicted protein						
	16	AsTeR009D10								
30	17	AsTeR032E02								
	18	AsTeR032H04								
	19	AsTeR004H04								
	20	AsTeR054B06								

Moreover, a ranked list of the genes that were identified with the highest frequency amongst the in total 190 clones sequenced (i.e. 102 spots selected after PLS analyses and 88 spots obtained after the differential analyses-See EP 08151584) (Table 6).

TABLE 6

Most frequently identified genes amongst the 190 clones sequenced												
ame												
ondrial oxylic acid orter - 51584												
nitate oxylase 112895)												
ed protein												

TABLE 6-continued

Most	frequently identified s	genes amongst the	190 clones seque	enced
Freq. Gene locus	# clones from differential approach	# clones from PLS approach	Regulation under itaconate producing conditions	er Gene name
2				
2				
2				
2				
2				
2				

The ATEG\_00972.1 gene, flanking cis-aconitate decarboxylase (ATEG\_09971.1-EP 07112895), and the putative mitochondrial tricarboxylate transporter protein (ATEG\_09970.1-EP08151584) were identified on two of the spots identified by PLS analysis (Table 6) and had an overall rank of 15 in the combined top 20 (Table 5). Just as the CAD gene and the MTAT gene, the ATEG\_09972.1 gene, was found to be upregulated under itaconic acid producing environmental conditions.

lator containing a zinc-finger domain (ATEG\_09969.1). This gene was not identified using our transcriptomics approach, but considering its localization it is expected that it is relevant for itaconic acid synthesis FIG. 2 shows that also the lovastatin pathway genes are located on this cluster, suggesting a link between both pathways which are (mainly) specific for *A. terreus*.

### Example 4

#### Homology Analysis of the ATEG\_09972.1 Gene

A BLAST search was performed in order to identify homologous to the predicted protein ATEG\_09972.1 (Table 7). High homologies were only found with genes from two other *A. terreus* strains. With other micro-organisms and 35 more specifically fungi, homologues were found although with a relatively low homology. Based on the annotation of these homologous genes and the major facilitator superfamily domain identified in this gene, ATEG\_09972.1 was identified as an itaconate exporter.

#### Example 5

#### (Co-)Expression of the ATEG\_09972.1 Gene in Aspergillus niger

In order to unambiguously establish that the ATEG\_09972.1 protein aids to the increased production of itaconic acid, a naturally non-itaconic acid producing fungal host was (co-)transformed with the CAD gene or transformed with the CAD and MTT (ATEG\_09970.1) gene were cotransformed with the ATEG\_09972.1 (MFS) gene.

Expression of the CAD (ATEG\_09971.1) Gene in Aspergillus niger

TABLE 7

	BLAST search results with ATEG_09972.1											
Rank	Protein	Best Hit	E value	Identity/ Similarity								
1	Predicted protein	XP_001209274.1 A. terreus	0.0	100%/100%								
2	unknown	AAD34564.1 A. terreus	0.0	92%/93%								
3	Unnamed protein product	BAE57135.1 A. oryzae	2e-160	70%/84%								
4	putitative MFS transporter	XP_749665.1 A. fumigatus	5e-135	64%/77%								
5	putitative MFS transporter	XP_001260160.1 N. fischeri	5e-134	65%/79%								
6	Hypothetical protein AN7512.2	XP_680781.1 A. nidulans	5e-123	59%/74%								
7	Hypothetical protein AN6019.2	XP_663623.1 A. nidulans	1e-105	52%/68%								
8	Unnamed protein product	BAE61268.1 A. oryzae	1e-91	45%/61%								
9	pH-responsive protein 2 precursor	XP_001215904.1 A. terreus	2e-91	68%/81%								
10	hypothetical protein Fgo2824.1	XP_383000.1 G. zeae	1e-81	47%/63%								

It appears that at least the gene coding for the cis-aconitate decarboxylase (ATEG\_09971.1) and the gene encoding the mitochondrial tricarboxylate transporter (ATEG\_9970.1) lie in the same cluster in the *A. terreus* genome (FIG. 2).

A gene neighbouring CAD, the mitochondrial tricarboxylate transporter and the itaconate exporter is a putative reguA PCR generated copy of the gene encoding the CAD protein (see EP07112895) was generated. For this purpose two sets of primers were generated as shown below. PCR amplification based on *A. terreus* NRRL1960 genomic DNA resulted in the isolation of PCR fragments from which the complete coding region of the gene encoding the CAD protein, could be isolated as BspHI-BamHI fragments.

CAD full sequence 1529 bp (SEQ ID NO: 11) ORIGIN (SEQ ID NO: 7)

BspHI cadfor40° C. 5'-ATCGTCATGACCAAGCAATCTG- 3'

(SEQ ID NO: 8) BspHI cadfor53° C. 5'-ATCGTCATGACCAAGCAATCTGCGGACA- 3' 1 ATGACCAAGC AATCTGCGGA CAGCAACGCA AAGTCAGGAG TTACGTCCGA AATATGTCAT 61 TGGGCATCCA ACCTGGCCAC TGACGACATC CCTTCGGACG TATTAGAAAG AGCAAAATAC 121 CTTATTCTCG ACGGTATTGC ATGTGCCTGG GTTGGTGCAA GAGTGCCTTG GTCAGAGAAG 181 TATGTTCAGG CAACGATGAG CTTTGAGCCG CCGGGGGCCT GCAGGGTGAT TGGATATGGA  ${\tt 241\ CAG} \underline{\tt gtaaatt}\ \underline{\tt ttattcactc}\ \underline{\tt tagacggtcc}\ \underline{\tt acaaagtata}\ \underline{\tt ctgacgatcc}\ \underline{\tt ttcgtatag} A$ (intron) 301 AACTGGGGCC TGTTGCAGCA GCCATGACCA ATTCCGCTTT CATACAGGCT ACGGAGCTTG 361 ACGACTACCA CAGCGAAGCC CCCCTACACT CTGCAAGCAT TGTCCTTCCT GCGGTCTTTG 421 CAGCAAGTGA GGTCTTAGCC GAGCAGGCA AAACAATTTC CGGTATAGAT GTTATTCTAG 481 CCGCCATTGT GGGGTTTGAA TCTGGCCCAC GGATCGGCAA AGCAATCTAC GGATCGGACC 541 TCTTGAACAA CGGCTGGCAT TGTGGAGCTG TGTATGGCGC TCCAGCCGGT GCGCTGGCCA 601 CAGGAAAGCT CTTCGGTCTA ACTCCAGACT CCATGGAAGA TGCTCTCGGA ATTGCGTGCA 661 CGCAAGCCTG TGGTTTAATG TCGGCGCAAT ACGGAGGCAT GGTAAAGCGT GTGCAACACG 721 GATTCGCAGC GCGTAATGGT CTTCTTGGGG GACTGTTGGC CCATGGTGGG TACGAGGCAA 781 TGAAAGGTGT CCTGGAGAGA TCTTACGGCG GTTTCCTCAA GATGTTCACC AAGGGCAACG 841 GCAGAGAGCC TCCCTACAAA GAGGAGGAAG TGGTGGCTGG TCTCGGTTCA TTCTGGCATA 901 CCTTTACTAT TCGCATCAAG CTCTATGCCT GCTGCGGACT TGTCCATGGT CCAGTCGAGG 961 CTATCGAAAA CCTTCAGGGG AGATACCCCG AGCTCTTGAA TAGAGCCAAC CTCAGCAACA 1021 TTCGCCATGT TCATGTACAG CTTTCAACGG CTTCGAACAG TCACTGTGGA TGGATACCAG 1081 AGGAGAGAC CATCAGTTCA ATCGCAGGGC AGATGAGTGT CGCATACATT CTCGCCGTCC 1141 AGCTGGTCGA CCAGCAATGT CTTTTGTCCC AGTTTTCTGA GTTTGATGAC AACCTGGAGA 1201 GGCCAGAAGT TTGGGATCTG GCCAGGAAGG TTACTTCATC TCAAAGCGAA GAGTTTGATC 1261 AAGACGGCAA CTGTCTCAGT GCGGGTCGCG TGAGGATTGA GTTCAACGAT GGTTCTTCTA

1321 TTACGGAAAG TGTCGAGAAG CCTCTTGGTG TCAAAGAGCC CATGCCAAAC GAACGGATTC 1381 TCCACAAATA CCGAACCCTT GCTGGTAGCG TGACGGACGA ATCCCGGGTG AAAGAGATTG 1441 AGGATCTTGT CCTCGGCCTG GACAGGCTCA CCGACATTAG CCCATTGCTG GAGCTGCTGA

(SEO ID NO: 9)

cadrev42° C. BamHI 3'-<u>TTTAGCGGTGACCATATTCCTAGGCCC</u>T- 5'

(SEQ ID NO: 10)

cadrev52° C. BamHI 3'-GGCATTTTAGCGGTGACCATATTCCTAGGCCCC- 5'

1501 ATTGCCCCGT AAAATCGCCA CTGGTATAA

#### Translation of CAD Encoding Gene

Total amino acid number: 490, MW = 52710 (SEQ ID NO: 12) 1 M T K Q S A D S N A K S G V T S E I C H 21 W A S N L A T D D I P S D V L E R A K Y

-continued

25

41 L I L D G I A C A W V G A R V P W S 61 Y V Q A T M S F E P P G A C R V I G A A A M T N 101 L D D Y H S E A P L H S A 121 F A A S E V L A E Q G K T 141 L A A T V G F E S G P R T G K A T Y G S 161 D L L N N G W H C G A 181 A T G K L F G L T P D S M E D A L G 201 C T Q A C G L M S A Q Y G G M V 221 H G F A A R N G L L G G L L A H G G 241 A M K G V L E R S Y G G F 261 N G R E P P Y K E E E V V A G L 281 H T F T T R T K I, Y A C C G I, V H G 301 E A T E N L O G R Y P E L L N R A N L S 321 N I R H V H V O L S T A S N S H C G 341 P E E R P I S S I A G O M S V A Y I L A LVDOOCLLSOFSEFDDNL 381 E R P E V W D L A R K V T S S 401 D Q D G N C L S A G R V R I E F N D 421 S I T E S V E K P L G V K E P M P N 441 I L H K Y R T L A G S V T D E S R V 461 I E D L V L G L D R L T D I S P L L E L 481 L N C P V K S P L V \*

The resulting BspHI-BamHI fragment was cloned into the *Aspergillus* expression vector pAN52-4amdS derived from *Aspergillus* expression vector pAN52-4. The *Aspergillus* expression vector pAN52-4amdS was derived by cloning the *Aspergillus* selection marker amdS into the *Aspergillus* expression vector pAN52-4 (EMBL accession #Z32699).

45

Subsequently, an *Aspergillus niger* strain AB1.13 (Mattern, I. E. et al., 1992, Mol. Gen. Genet. 234:332-336) was transformed with the CAD expression vector. AmdS transformants resulting for this experiment were purified by single colony purification and retested for their AmdS+ phenotype.

Co-Expression of the CAD Gene and the ATEG 09970.1 Gene in *Aspergillus niger* 

26

The ATEG\_09970.1 gene (MTT) was synthesized (Gene-Art) and cloned into *Aspergillus niger* expression vector pAN52-5doubleNotI by restriction enzyme cutting sites of double NotI. The expression vector pAN52-5doubleNotI was derived by adding an extra NotI site in the *Aspergillus* expression vector pAN52-4 (EMBL accession #Z32699). Moreover, the codons of the clone were optimized for expression in the *Aspergillus niger* strain.

Translation of MTT cds (1-861) (SEQ ID NOS:13-14)

Universal code

Total amino acid number: 286, MW = 31503

Max ORF starts at AA pos 1 (may be DNA pos 1) for 286 AA(858 bases), MW = 31503

1 ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCT

1 M S I Q H F R V A L I P F F A A F C L P

61 GTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCA
21 V F A H P E T L V K V K D A E D Q L G A

121 CGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCC
41 R V G Y I E L D L N S G K I L E S F R P

181 GAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCC 61 E E R F P M M S T F K V L L C G A V L S

#### -continued

241	CGT	ATT	GAC	GCC	GGG	CAA	GAG	CAA	CTC	GGT	CGC	CGC	ATA	CAC	TAT	TCT	CAG	AAT	GAC	TTG
81	R	I	D	A	G	Q	E	Q	L	G	R	R	I	Н	Y	S	Q	И	D	L
301	GTT	GAG	TAC	TCA	CCA	GTC	ACA	GAA	AAG	CAT	CTT	ACG	GAT	GGC	ATG	ACA	GTA	AGA	GAA.	TTA
101	V	E	Y	S	P	V	T	E	K	Н	L	Т	D	G	M	T	V	R	E	L
361	${\tt TGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTT$																			
121	C	S	A	A	I	Т	M	S	D	N	Т	A	A	N	L	L	L	Т	Т	I
421	1 GGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTT																			
141	G	G	P	K	E	L	T	A	F	L	Н	N	M	G	D	Н	V	Т	R	L
481	481 GATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATG																			
161	D	R	W	Е	Р	Е	L	N	Е	A	I	P	N	D	Е	R	D	Т	Т	М
541	541 CCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACT																			
181	P	V	A	М	A	Т	Т	L	R	K	L	L	Т	G	E	L	L	Т	L	A
601	TCC	CGG	CAA	CAA	TTA	ATA	GAC	TGG	ATG	GAG	GCG	GAT	'AAA	GTT	GCA	GGA	CCA	СТТ	CTG	CGC
201	S	R	Q	Q	L	I	D	M	М	Е	A	D	K	V	A	G	P	L	L	R
661	TCG	GCC	CTT	CCG	GCT	GGC	TGG	TTT	ATT	GCT	GAT	AAA	TCT	GGA	.GCC	GGT	GAG	CGT	GGG	TCT
221	S	A	L	P	A	G	M	F	I	A	D	K	S	G	A	G	E	R	G	S
721	CGC	GGT	ΔTC	בתר	GCA	GCA	стс	GGG	CCA	GAT	GGT	ΔΔG	יכככ	ידיכיכי	ССТ	ΔTC	GTA	стт	'בידר	TAC
241	R		I	I		A		G	P	D	G	K		s	R	I	v			Y
701	ACG	A C C	aca	አረሞ	CAG	CCA	አረጥ	አ ጥር	CI N TI	CA A	CCA	አአጥ	יאכיא	CAG	አጥሮ	czcm	CAC	אידא	CCT	ccc
261	T			AGI S		A A		M	D	GAA E	R		R R	0	I	A A	GAG E	I	G	A
	-	-	-		*		-		_	_				£	_		_	-	-	
841	TCA	CTG	ATT	AAG	CAT	TGG	TAA													
281	S	T.	Т	K	Н	W	*													

Subsequently, an *Aspergillus niger* strain AB1.13 (Mattern, I. E. et al., 1992, Mol. Gen. Genet. 234:332-336) was co-transformed with the CAD expression vector and the MTT expression vector. AmdS transformants resulting for this experiment were purified by single colony purification and retested for their AmdS+ phenotype.

Co-Expression of the CAD Gene, MTT Gene (ATEG\_09970.1) Together with the ATEG-09972.1 Gene in *Aspergillus niger* 

The ATEG-09972.1 (MFS) gene was synthesized (Gene-Art) and cloned into *Aspergillus niger* expression vector pAN52-5doubleNotI by restriction enzyme cutting sites of double NotI. The expression vector pAN52-5doubleNotI was derived by adding an extra NotI site in the *Aspergillus* expression vector pAN52-4 (EMBL accession #Z32699). Moreover, codons of the clone were optimized for expression in the *Aspergillus niger* strain.

Subsequently, an *Aspergillus niger* strain AB1.13 (Mattern, I. E. et al., 1992, Mol. Gen. Genet. 234:332-336) was co-transformed with the CAD expression vector, the MTT expression vector and the MFS expression vector. AmdS transformants resulting for this experiment were purified by 50 single colony purification and retested for their AmdS+ phenotype.

Analysis of A. niger Transformants for Itaconic Acid Produc-

Several positive transformants and the parental host strain 55 were subsequently cultured in Shake Flask in MM medium supplied with uridine containing glucose as C-source and nitrate as N-source. Medium samples from the various cultures were analyzed by HPLC for the presence of itaconic acid (Table 8).

Shake Flask Medium Compositions:

Per litre: 0.52 g of KCl, 2.4 g of NaNO<sub>3</sub>, 1.56 g of KH<sub>2</sub>PO<sub>4</sub>, 0.24 g of MgSO<sub>4</sub>\*7H<sub>2</sub>O, 5 mg of Fe(III)SO<sub>4</sub>\*7H<sub>2</sub>O, 5 mg of MnCl<sub>2</sub>\*4H<sub>2</sub>O, 0.022 g of ZnSO<sub>4</sub>\*7H<sub>2</sub>O, 0.011 g of H<sub>3</sub>BO<sub>3</sub>, 1.7 mg of CoCl<sub>2</sub>\*6H<sub>2</sub>O and 2.44 g of uridine, 100 g of glucose 65 as a carbon source. All media were prepared in demineralised water.

HPLC analysis was performed with a reversed phase column, using a Develosil<sup>TM</sup> 3 μm RP-Aqueous C30 140A column at a constant temperature of 25° C., with elution with 20 mM NaH2PO4, pH 2.25 and acetonitril. Compounds were detected by UV at 210 nm using a Waters 2487 Dual wavelength Absorbance detector (Milford, Mass., USA). Retention time of itaconic acid was 18.82 min.

TABLE 8

Itaconic acid concentration in the culture fluid of the A. niger AB1.13 transformants cultivated in shake flasks. Aspergillus niger AB 1.13 transformants (AB 1.13 CAD)

	strain	code	time (hrs)	itaconic acid mg/g wet weight
5	AB 1.13	WT	54	0
	AB 1.13 CAD	5.1	54	1.0
	AB 1.13 CAD	7.2	54	0.7
	AB 1.13 CAD	10.1	54	1.4
	AB 1.13 CAD	14.2	54	1.2
	AB 1.13 CAD	16.1	54	1.2
)	AB 1.13 CAD + MTT	4.1	54	1.3
	AB 1.13 CAD + MTT	6.2	54	1.5
	AB 1.13 CAD + MTT	2.2.1	54	2.2
	AB 1.13 CAD + MTT + MFS	9.2.1*	54	2.3
	AB 1.13 CAD + MTT + MFS	9.2.2*	54	2.5
	AB 1.13 CAD + MTT + MFS	9.4.1*	54	2.5
5	AB 1.13 CAD + MTT + MFS	12.1.1	54	2.3

\*Duplicate isolates of the same transformant.

No itaconic acid was detected in the supernatant of the parental strain while in the culture fluid of the strains containing the CAD gene (strains marked CAD), itaconic acid was detected.

In both the culture fluid of the strains containing the CAD gene and the strains containing both the CAD gene and MTT gene (strains marked CAD+MTT) and the strains containing the CAD, the MTT and the MFS gene (strains marked CAD+MTT+MFS), itaconic acid was detected (Table 8). In all MFS

expressing strains more itaconic acid was produced in the culture fluid than in the strains expressing only the CAD gene, or the CAD and the MTT gene. Moreover, the average itaconic acid concentration was higher in the culture fluid of the strains expressing the MFS, the CAD and the MTT gene

compared to the transformants expressing only the CAD or the CAD+MTT gene: 2.4 mg itaconic acid/g mycelial wet weight versus 1.1 mg itaconic acid/g mycelial wet weight (CAD gene only) and 1.7 mg itaconic acid/g mycelial wet weight (CAD+MTT gene—Table 8).

SEQUENCE LISTING

```
<160> NUMBER OF SEQ ID NOS: 14
<210> SEQ ID NO 1
<211> LENGTH: 1392
<212> TYPE: DNA
<213> ORGANISM: Aspergillus terreus
<400> SEQUENCE: 1
atgggccacg gtgacactga gtccccgaac ccaacgacga ccacggaagg tagcggacaa
aacgagccag agaaaaaggg ccgtgatatt ccattatgga gaaaatgtgt cattacgttt
gttgttagtt ggatgactct agtcgttact ttctccagta cttgtcttct tcctgccgcc
cctgaaatcg cgaatgaatt tgatatgact gtcgagacta tcaacatctc caatgctggt
                                                                       240
gtectagttg ccatgggata tteatecete atatggggte ccatgaacaa gttagtegge
                                                                       300
cggcggacat catacaatct ggccatttca atgctttgtg catgctccgc tggaacggca
                                                                       360
gcggcgataa acgaggaaat gttcatagcg ttcagagtgt tgagcggctt aaccggaacc
                                                                       420
tegtteatgg teteaggeea aactgttett geagatatet ttgageetgt aegaateaca
                                                                       480
egecetegte tecceaattg egaaaactaa teegttegtg egeaggttta eegtgggaeg
                                                                       540
geogtaggtt tetteatgge egggaetett tetggeeetg caataggtae gtaceetget
                                                                       600
gcaagtacta gaactcccaa caggaactaa ttgtatgagc aggcccctgc gtgggagggg
                                                                       660
{\tt tcatcgtcac} \ {\tt tttcacgagt} \ {\tt tggcgtgtta} \ {\tt tcttctggct} \ {\tt tcaactaggt} \ {\tt atgagcgggc}
                                                                       720
tggggctcgt gctttctctg ctatttttcc cgaaaatcga aggaaattct gagaaggtct
                                                                       780
caacggcgtt taaaccgacc acacttgtca caatcatatc gaaattctcc ccaacggatg
                                                                       840
tgctcaagca gtgggtgtat ccaaatgtct ttcttgccgt aagtgtctgg gacatatacc
                                                                       900
ctctgcatct actggaaaac gagatgctca tgccacaaat caaaggactt atgctgtggc
                                                                       960
ctcctggcaa tcacgcaata ttcgatcctg acttcagctc gtgccatatt caactcacga
                                                                      1020
tttcatttaa cgactgccct agtatcgggt ctcttctacc tcgctccagg tgccgggttc
                                                                      1080
ctgataggca gtctcgtcgg cggtaaactt tcggatcgca ccgttcggag atacatagta
                                                                      1140
aagegeggat teegteteee teaggatega eteeacageg ggeteateae attgttegee
                                                                      1200
gtgctgcccg caggaacgct catttacggg tggacactcc aagaggataa gggtgatatg
                                                                      1260
gtagtgccca taatcgcggc gttcttcgcg ggctgggggc tcatgggcag ttttaactgc
ctgaacactt acgtggctgg tttgttccac accctcattt atctattccc tttgtgtaca
                                                                      1380
                                                                      1392
tgcccacaat aa
<210> SEQ ID NO 2
<211> LENGTH: 1212
<212> TYPE: DNA
<213> ORGANISM: Aspergillus terreus
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(1212)
<400> SEQUENCE: 2
atg ggc cac ggt gac act gag tcc ccg aac cca acg acg acc acg gaa
                                                                        48
Met Gly His Gly Asp Thr Glu Ser Pro Asn Pro Thr Thr Thr Glu
                                     10
                                                         15
```

					gag Glu							96
					ttt Phe 40							144
					ctt Leu							192
					gag Glu							240
					tca Ser							288
					tca Ser							336
					gca Ala 120							384
					ggc Gly							432
					gat Asp							480
					gcc Ala							528
					atc Ile							576
					atg Met 200							624
					gaa Glu							672
			Thr	Leu	gtc Val		Ile	Ser				720
					gtg Val							768
					atc Ile							816
-	_	_			cga Arg 280			_		_	-	864
_				_	cca Pro		_		_		 _	912
					gat Asp							960
_	_		_		cag Gln	_	_		_			1008

-continue

		-continued
325	330	335
	ctg ccc gca gga acg ctc a Leu Pro Ala Gly Thr Leu 1 345	
	ggt gat atg gta gtg ccc a Gly Asp Met Val Val Pro I 360	
	ctc atg ggc agt ttt aac t Leu Met Gly Ser Phe Asn 0 375	
	cac acc ctc att tat cta t His Thr Leu Ile Tyr Leu F 390 395	
tgc cca caa taa Cys Pro Gln		1212
<pre>&lt;210&gt; SEQ ID NO 3 &lt;211&gt; LENGTH: 403 &lt;212&gt; TYPE: PRT &lt;213&gt; ORGANISM: Aspe</pre>	ergillus terreus	
<400> SEQUENCE: 3		
Met Gly His Gly Asp 1 5	Thr Glu Ser Pro Asn Pro 1	Thr Thr Thr Glu 15
Gly Ser Gly Gln Asn 20	Glu Pro Glu Lys Lys Gly A 25	Arg Asp Ile Pro Leu 30
Trp Arg Lys Cys Val 35	Ile Thr Phe Val Val Ser 7	Trp Met Thr Leu Val 45
Val Thr Phe Ser Ser 50	Thr Cys Leu Leu Pro Ala F 55	Ala Pro Glu Ile Ala 60
Asn Glu Phe Asp Met 65	Thr Val Glu Thr Ile Asn I	Ile Ser Asn Ala Gly 80
Val Leu Val Ala Met 85	Gly Tyr Ser Ser Leu Ile 7	Trp Gly Pro Met Asn 95
Lys Leu Val Gly Arg 100	Arg Thr Ser Tyr Asn Leu A	Ala Ile Ser Met Leu 110
Cys Ala Cys Ser Ala 115	Gly Thr Ala Ala Ala Ile A	Asn Glu Glu Met Phe 125
Ile Ala Phe Arg Val	Leu Ser Gly Leu Thr Gly 1	Thr Ser Phe Met Val 140
Ser Gly Gln Thr Val 145	Leu Ala Asp Ile Phe Glu F 150 155	Pro Val Tyr Arg Gly 160
Thr Ala Val Gly Phe 165	Phe Met Ala Gly Thr Leu S 170	Ser Gly Pro Ala Ile 175
Gly Pro Cys Val Gly 180	Gly Val Ile Val Thr Phe 1	Thr Ser Trp Arg Val
Ile Phe Trp Leu Gln 195	Leu Gly Met Ser Gly Leu C 200	Gly Leu Val Leu Ser 205
Leu Leu Phe Phe Pro 210	Lys Ile Glu Gly Asn Ser C	Glu Lys Val Ser Thr 220
Ala Phe Lys Pro Thr 225	Thr Leu Val Thr Ile Ile S 230 235	Ser Lys Phe Ser Pro 240
Thr Asp Val Leu Lys 245	Gln Trp Val Tyr Pro Asn V	Val Phe Leu Ala Asp 255
Leu Cys Cys Gly Leu 260	Leu Ala Ile Thr Gln Tyr S 265	Ser Ile Leu Thr Ser 270

-continued

Ala Arg Ala Ile Phe Asn Ser Arg Phe His Leu Thr Thr Ala Leu Val 280 Ser Gly Leu Phe Tyr Leu Ala Pro Gly Ala Gly Phe Leu Ile Gly Ser 290 295 Leu Val Gly Gly Lys Leu Ser Asp Arg Thr Val Arg Arg Tyr Ile Val Lys Arg Gly Phe Arg Leu Pro Gln Asp Arg Leu His Ser Gly Leu Ile 330 Thr Leu Phe Ala Val Leu Pro Ala Gly Thr Leu Ile Tyr Gly Trp Thr Leu Gln Glu Asp Lys Gly Asp Met Val Val Pro Ile Ile Ala Ala Phe Phe Ala Gly Trp Gly Leu Met Gly Ser Phe Asn Cys Leu Asn Thr Tyr Val Ala Gly Leu Phe His Thr Leu Ile Tyr Leu Phe Pro Leu Cys Thr 395 Cys Pro Gln <210> SEQ ID NO 4 <211> LENGTH: 1803 <212> TYPE: DNA <213 > ORGANISM: Aspergillus oryzae <400> SEOUENCE: 4 atgggtcaac ccgatcttga atctcaaacc cccaaaacta tagacggggc cacgaaagag 60 aaggaagaga aaggcagcaa agttgaaaag ggttacggtc ttcctttgtg gcggaaatgt 120 atcatectet tegtegteag ttggatgaet ettgeegtta eettetegag eacatetett 180 cttcctgcaa cccccgagat cgccgaggag ttcaacacca ccactgagac cctcaacatc 240 accaatgeeg gegttttget ggetatggge ttetegtege ttatetgggg teeettgaat 300 aatotgattg gaagaaggot otogtataac attgogatot toatgototg tgtgtgttog 360 gcagcgacgg gggctgcagt agacttgaag atgtttacgg cttttcgagt gttgagcggt 420 ttgacgggga cgtcattcat ggtatcggga cagaccattc tggcggacat ttttgaaccg 480 gtactttttc gctacctttc tctatgctcc tgtgtactag tcagttaagt actaataatg 540 geegataggt tgteegtggt acageegtgg gattetttat ggetggatet gteteeggte ctgcaattgg gccctgtatc ggaggcctca tcgtcacctt ctccagctgg cgcaatatct actggctcca agtcggcatg acaggattcg gcctggttct agccattctc ttcgtccccg aaatcaaaca ggaatccaaa gaggaacccg aagaaaaaga gaagaggaca gtactttccg 840 contacquet etteaateee eteeqaatet teaqacaatq qqtetateee aacqtettet 900 totocqtaaq cootcottoo actaactaaa actaaaccaq acotcatcaa ctaacaatac ctccccaaaa aggacctaac ctgcggtctc ctcgccacat tccaatactc gctcctcaca 960 tecgeceget caatetteaa teccegette caceteacaa cageacteat eteeggeete 1020 ttctacctcg ccccaggagc tggcttcctg atcggcagca tcatcggcgg caaactctcc 1080 gaccgtaccg tccgcaagta catcgtccgt cgcggcttcc gattgcccca ggatcgcctc 1140 aactccggcc tcgtcaccct gttcgccgtg ctacccgttt cggcgctgat ctacggctgg 1200

accetgeagg aggagaaggg tggtatggte gtgccgattt tggcggcgtt ttttgcaggt

tgggggctta tgggcagttt taatactttg aacacttatg ttgctggtga gtttttccat

1260

1320

				-cont	- IIIU	ea —		
ccatccatcc atccat	ctat ctttct	ttet ttett	tcttt t	gtttcct	gt c	acgt	gtgca	1380
aaggcgtgga atggtt	gcta ataato	gatac agagg	ctctg c	cgcataa	gc g	ctcc	gaagt	1440
catcgctgga aagtat	atca tccagt	atat ctttt	cggcg g	ggagtag	tg c	gctt	gtggt	1500
gccgattatt aatgcc	attg gggttg	gggtg gactt	ttacc a	tttgtat	gt ti	tgac	cttct	1560
tettettett ettett	cttc ttcttc	cttct tcttc	ttctt c	ttcttct	tc t	tctt	cttct	1620
tettettett ettett	cttc tttttt	gttt gttac	gggag g	ttatatg	tg a	ctga	ctaat	1680
tgtgtaggtg tgatct	tttc catcat	cggt ggtct	gttaa c	gatggct	ac c	gcgc	gatgg	1740
ggtctggata tgcaac	aatg ggtgga	agagg aagtt	ccgca t	tcatgat	aa a	ccag	ggttt	1800
tga								1803
<pre>&lt;210&gt; SEQ ID NO 5 &lt;211&gt; LENGTH: 141 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: A &lt;220&gt; FEATURE: &lt;221&gt; NAME/KEY: C &lt;222&gt; LOCATION: ( &lt;400&gt; SEQUENCE: 5 atg ggt caa ccc g</pre>	spergillus OS 1)(1419)		c ccc a	aa act	ata (	gac	aaa	48
Met Gly Gln Pro A	_		r Pro L		Ile	_		
gcc acg aaa gag a Ala Thr Lys Glu L 20			_	al Glu	_			96
ggt ctt cct ttg t Gly Leu Pro Leu T 35		-		_	_	_		144
atg act ctt gcc g Met Thr Leu Ala V 50				eu Leu				192
ccc gag atc gcc g Pro Glu Ile Ala G 65			_	-		Asn		240
acc aat gcc ggc g Thr Asn Ala Gly V 8	al Leu Leu		y Phe S		Leu :			288
ggt ccc ttg aat a Gly Pro Leu Asn A 100				er Tyr				336
atc ttc atg ctc t Ile Phe Met Leu C 115								384
ttg aag atg ttt a Leu Lys Met Phe T 130			u Ser G		_		-	432
tca ttc atg gta t Ser Phe Met Val S 145						Glu	-	480
gtt gtc cgt ggt a Val Val Arg Gly T 1			e Met A		Ser '	_		528
ggt cct gca att g Gly Pro Ala Ile G 180				le Val				576
agc tgg cgc aat a Ser Trp Arg Asn I								624

-continued
------------

												COII	CIII	ueu		
		195					200					205				
_	gtt Val 210		_				_		_			_	_			672
	gaa Glu		_	_			_			_			_		_	720
	ttc Phe															768
	ttc Phe															816
	ctc Leu			_	_						_					864
	gca Ala 290															912
	atc Ile															960
	tac Tyr															1008
	ggc Gly															1056
	ggc Gly															1104
	gcg Ala 370															1152
	aac Asn															1200
	gct Ala		_				_				_			_	_	1248
	ctt Leu															1296
	att Ile															1344
	gcg Ala 450															1392
-	att Ile		-					tga								1419
<21 <21	0 > SI 1 > LI 2 > T 3 > OI	ENGTI YPE :	H: 4' PRT	72	ergi:	llus	ory:	zae								

<400> SEQUENCE: 6

Met Gly Gln Pro Asp Leu Glu Ser Gln Thr Pro Lys Thr Ile Asp Gly

-	continued
-	continued

				5					10					15	
	Thr	Lys	Glu 20		Glu	Glu	Lys	Gly 25		Lys	Val	Glu	Lys		Tyr
Gly	Leu	Pro 35	Leu	Trp	Arg	Lys	Cys 40	Ile	Ile	Leu	Phe	Val 45	Val	Ser	Trp
Met	Thr 50	Leu	Ala	Val	Thr	Phe 55	Ser	Ser	Thr	Ser	Leu 60	Leu	Pro	Ala	Thr
Pro 65	Glu	Ile	Ala	Glu	Glu 70	Phe	Asn	Thr	Thr	Thr 75	Glu	Thr	Leu	Asn	Ile 80
Thr	Asn	Ala	Gly	Val 85	Leu	Leu	Ala	Met	Gly 90	Phe	Ser	Ser	Leu	Ile 95	Trp
Gly	Pro	Leu	Asn 100	Asn	Leu	Ile	Gly	Arg 105	Arg	Leu	Ser	Tyr	Asn 110	Ile	Ala
Ile	Phe	Met 115	Leu	Сув	Val	Cys	Ser 120	Ala	Ala	Thr	Gly	Ala 125	Ala	Val	Asp
Leu	Lys 130	Met	Phe	Thr	Ala	Phe 135	Arg	Val	Leu	Ser	Gly 140	Leu	Thr	Gly	Thr
Ser 145	Phe	Met	Val	Ser	Gly 150	Gln	Thr	Ile	Leu	Ala 155	Asp	Ile	Phe	Glu	Pro 160
Val	Val	Arg	Gly	Thr 165	Ala	Val	Gly	Phe	Phe 170	Met	Ala	Gly	Ser	Val 175	Ser
Gly	Pro	Ala	Ile 180	Gly	Pro	CAa	Ile	Gly 185	Gly	Leu	Ile	Val	Thr 190	Phe	Ser
Ser	Trp	Arg 195	Asn	Ile	Tyr	Trp	Leu 200	Gln	Val	Gly	Met	Thr 205	Gly	Phe	Gly
Leu	Val 210	Leu	Ala	Ile	Leu	Phe 215	Val	Pro	Glu	Ile	Lys 220	Gln	Glu	Ser	ГЛа
Glu 225	Glu	Pro	Glu	Glu	Lys 230	Glu	Lys	Arg	Thr	Val 235	Leu	Ser	Ala	Leu	Arg 240
Leu	Phe	Asn	Pro	Leu 245	Arg	Ile	Phe	Arg	Gln 250	Trp	Val	Tyr	Pro	Asn 255	Val
Phe	Phe	Ser	Asp 260	Leu	Thr	Cys	Gly	Leu 265	Leu	Ala	Thr	Phe	Gln 270	Tyr	Ser
Leu	Leu	Thr 275	Ser	Ala	Arg	Ser	Ile 280	Phe	Asn	Pro	Arg	Phe 285	His	Leu	Thr
Thr	Ala 290	Leu	Ile	Ser	Gly	Leu 295	Phe	Tyr	Leu	Ala	Pro 300	Gly	Ala	Gly	Phe
Leu 305	Ile	Gly	Ser	Ile	Ile 310	Gly	Gly	Lys	Leu	Ser 315	Asp	Arg	Thr	Val	Arg 320
ГÀа	Tyr	Ile	Val	Arg 325	Arg	Gly	Phe	Arg	Leu 330	Pro	Gln	Asp	Arg	Leu 335	Asn
Ser	Gly	Leu	Val 340	Thr	Leu	Phe	Ala	Val 345	Leu	Pro	Val	Ser	Ala 350	Leu	Ile
Tyr	Gly	Trp 355	Thr	Leu	Gln	Glu	Glu 360	ГЛа	Gly	Gly	Met	Val 365	Val	Pro	Ile
Leu	Ala 370	Ala	Phe	Phe	Ala	Gly 375	Trp	Gly	Leu	Met	Gly 380	Ser	Phe	Asn	Thr
Leu 385	Asn	Thr	Tyr	Val	Ala 390	Glu	Ala	Leu	Pro	His 395	Lys	Arg	Ser	Glu	Val 400
Ile	Ala	Gly	Lys	Tyr 405	Ile	Ile	Gln	Tyr	Ile 410	Phe	Ser	Ala	Gly	Ser 415	Ser
Ala	Leu	Val	Val 420	Pro	Ile	Ile	Asn	Ala 425	Ile	Gly	Val	Gly	Trp 430	Thr	Phe

```
Thr Ile Cys Val Ile Phe Ser Ile Ile Gly Gly Leu Leu Thr Met Ala
                            440
Thr Ala Arg Trp Gly Leu Asp Met Gln Gln Trp Val Glu Arg Lys Phe
                        455
Arg Ile His Asp Lys Pro Gly Phe
<210> SEQ ID NO 7
<211> LENGTH: 22
<212> TYPE: DNA
<213 > ORGANISM: Artificial
<220> FEATURE:
<223 > OTHER INFORMATION: primer
<400> SEQUENCE: 7
atcgtcatga ccaagcaatc tg
<210> SEQ ID NO 8
<211> LENGTH: 28
<212> TYPE: DNA
<213 > ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: primer
<400> SEQUENCE: 8
atcgtcatga ccaagcaatc tgcggaca
                                                                       28
<210> SEQ ID NO 9
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: primer
<400> SEQUENCE: 9
tttagcggtg accatattcc taggccct
                                                                       28
<210> SEQ ID NO 10
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223 > OTHER INFORMATION: primer
<400> SEQUENCE: 10
ggcattttag cggtgaccat attcctaggc ccc
                                                                       33
<210> SEQ ID NO 11
<211> LENGTH: 1529
<212> TYPE: DNA
<213> ORGANISM: Aspergillus terreus
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1) .. (243)
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (300) .. (1526)
<400> SEQUENCE: 11
atg acc aag caa tct gcg gac agc aac gca aag tca gga gtt acg tcc
                                                                       48
Met Thr Lys Gln Ser Ala Asp Ser Asn Ala Lys Ser Gly Val Thr Ser
                                    10
gaa ata tgt cat tgg gca tcc aac ctg gcc act gac gac atc cct tcg
                                                                       96
Glu Ile Cys His Trp Ala Ser Asn Leu Ala Thr Asp Asp Ile Pro Ser
            20
                               25
```

								ctt Leu									144
								tgg Trp									192
								gcc Ala									240
cag Gln	gtaa	aatt	ta t	tca	ctcta	ag a	eggto	ccaca	a aaq	gtata	actg	acga	atcct	ttc (	gtataç	a	299
								atg Met 90									347
								agc Ser									395
								gca Ala									443
_								gat Asp	_			_	_				491
								ggc Gly									539
								gga Gly 170									587
								ttc Phe									635
								acg Thr									683
								cgt Arg									731
								ttg Leu									779
								tac Tyr 250									827
	_				_			ccc Pro					_				875
-								acc Thr				_		_			923
	_	_	_			_		ggt Gly		_		-		_			971
								ttg Leu								1	019
	_		-		-	_		tca Ser 330	_	-	_		-		_	1	067

gga tgg ata cca gag gag aga ccc atc agt tcc Gly Trp Ile Pro Glu Glu Arg Pro Ile Ser Ser 340  agt gtc gca tac att ctc gcc gtc cag ctg gtc Ser Val Ala Tyr Ile Leu Ala Val Gln Leu Val 355  ttg tcc cag ttt tct gag ttt gat gac aac ctc Leu Ser Gln Phe Ser Glu Phe Asp Asp Asp Leu 370  tgg gat ctg gcc agg aag gtt act tca tct cac Trp Asp Leu Ala Arg Lys Val Thr Ser Ser Gln 390  caa gac ggc aac tgt ctc agt gcg ggt cgc gtc Gln Asp Gly Asn Cys Leu Ser Ala Gly Arg Val 410  gat ggt tct tct att acg gaa agt gtc gag aac	er Ile Ala Gly Gln Met 350  cc gac cag caa tgt ctt 1163 al Asp Gln Gln Cys Leu 365  cg gag agg cca gaa gtt eu Glu Arg Pro Glu Val 385  aa agc gaa gag ttt gat 1259 an Ser Glu Glu Phe Asp 400  cg agg att gag ttc aac 1307
Ser Val Ala Tyr Ile Leu Ala Val Gln Leu Val 355  ttg tcc cag ttt tct gag ttt gat gac aac ctc Leu Ser Gln Phe Ser Glu Phe Asp Asp Asn Lei 370  tgg gat ctg gcc agg aag gtt act tca tct cast Trp Asp Leu Ala Arg Lys Val Thr Ser Ser Gln 395  caa gac ggc aac tgt ctc agt gcg ggt cgc gtg Gln Asp Gly Asn Cys Leu Ser Ala Gly Arg Val 410	al Asp Gln Gln Cys Leu 365  ag gag agg cca gaa gtt 1211 eu Glu Arg Pro Glu Val 385  aa agc gaa gag ttt gat 1259 ln Ser Glu Glu Phe Asp 400  ag agg att gag ttc aac 1307
Leu Ser Gln Phe Ser Glu Phe Asp Asp Asp Leu 370	eu Glu Arg Pro Glu Val 385  aa agc gaa gag ttt gat 1259 In Ser Glu Glu Phe Asp 400  cg agg att gag ttc aac 1307
Trp Asp Leu Ala Arg Lys Val Thr Ser Ser Gli 390 caa gac ggc aac tgt ctc agt gcg ggt cgc gtc Gln Asp Gly Asn Cys Leu Ser Ala Gly Arg Val 410	In Ser Glu Glu Phe Asp 400 Eg agg att gag ttc aac 1307
Gln Asp Gly Asn Cys Leu Ser Ala Gly Arg Va. 405 410	
gat ggt tot tot att acg gaa agt gto gag aag	415
Asp Gly Ser Ser Ile Thr Glu Ser Val Glu Ly: 420 425	
gag ccc atg cca aac gaa cgg att ctc cac aac Glu Pro Met Pro Asn Glu Arg Ile Leu His Lys 435 440	
ggt agc gtg acg gac gaa tcc cgg gtg aaa gag Gly Ser Val Thr Asp Glu Ser Arg Val Lys Glu 450 455 460	lu Ile Glu Asp Leu Val
ctc ggc ctg gac agg ctc acc gac att agc ccc Leu Gly Leu Asp Arg Leu Thr Asp Ile Ser Pro 470 475	
aat tgc ccc gta aaa tcg cca ctg gta taa Asn Cys Pro Val Lys Ser Pro Leu Val 485 490	1529
<210> SEQ ID NO 12 <211> LENGTH: 490 <212> TYPE: PRT <213> ORGANISM: Aspergillus terreus	
<400> SEQUENCE: 12	
Met Thr Lys Gln Ser Ala Asp Ser Asn Ala Lys 1 5 10	ys Ser Gly Val Thr Ser 15
	15
1 5 10 Glu Ile Cys His Trp Ala Ser Asn Leu Ala Th	15 nr Asp Asp Ile Pro Ser 30
1 5 10 Glu Ile Cys His Trp Ala Ser Asn Leu Ala Th: 20 25 Asp Val Leu Glu Arg Ala Lys Tyr Leu Ile Leu	15 nr Asp Asp Ile Pro Ser 30 eu Asp Gly Ile Ala Cys 45
1 5 10 10 Glu Ile Cys His Trp Ala Ser Asn Leu Ala Thr 25 25 Asp Val Leu Glu Arg Ala Lys Tyr Leu Ile Leu 35 Ala Trp Val Gly Ala Arg Val Pro Trp Ser Glu	15  nr Asp Asp Ile Pro Ser 30  eu Asp Gly Ile Ala Cys 45  lu Lys Tyr Val Gln Ala 60  rg Val Ile Gly Tyr Gly
1 Solution of the state of the	15  nr Asp Asp Ile Pro Ser 30  eu Asp Gly Ile Ala Cys 45  lu Lys Tyr Val Gln Ala 60  rg Val Ile Gly Tyr Gly 5
1 Solution of the state of the	15  nr Asp Asp Ile Pro Ser 30  eu Asp Gly Ile Ala Cys 45  lu Lys Tyr Val Gln Ala 60  rg Val Ile Gly Tyr Gly 80  nr Asn Ser Ala Phe Ile 95
1       5       10         Glu Ile Cys His 20       Trp Ala Ser Asn Leu Ala Thr 25         Asp Val Leu 35       Glu Arg Ala Lys Tyr Leu Ile Leu 40         Ala Trp Val Gly Ala Arg 55       Pro Trp Ser Glu 55         Thr Met Ser Phe Glu Pro 70       Pro Gly Ala Cys Arg 75         Gln Lys Leu Gly Pro 85       Val Ala Ala Ala Met Thr 86         Gln Ala Thr Glu Leu Asp Asp Tyr His Ser Glu	15  nr Asp Asp Ile Pro Ser 30  eu Asp Gly Ile Ala Cys 45  lu Lys Tyr Val Gln Ala 60  rg Val Ile Gly Tyr Gly 5  nr Asn Ser Ala Phe Ile 95  lu Ala Pro Leu His Ser 110
1       5       10       10         Glu Ile Cys His 20       Trp Ala Ser Asn Leu Ala The 25       Asn Leu Ala The 25       Ala The 25         Asp Val Leu Ser Glu Arg Ala Lys 55       Tyr Leu Ile Leu Ser Glu 55       Trp Ser Glu 65         Thr Met Ser Phe Glu Pro Pro Pro Gly Ala Cys 75       Arg 75         Gln Lys Leu Gly Pro Val Ala Ala Ala Ala Ala Met 75       Trp 90         Gln Ala Thr Glu Leu Asp Asp Tyr His 5er Glu 105       Ala Ser Ile Val Leu Pro Ala Val Phe Ala Ala Ala	15  nr Asp Asp Ile Pro Ser 30  eu Asp Gly Ile Ala Cys 45  lu Lys Tyr Val Gln Ala 60  rg Val Ile Gly Tyr Gly 80  nr Asn Ser Ala Phe Ile 95  lu Ala Pro Leu His Ser 110  la Ser Glu Val Leu Ala 125

-continued

Asp Leu Leu Asn Asn Gly Trp His Cys Gly Ala Val Tyr Gly Ala Pro 170 Ala Gly Ala Leu Ala Thr Gly Lys Leu Phe Gly Leu Thr Pro Asp Ser Met Glu Asp Ala Leu Gly Ile Ala Cys Thr Gln Ala Cys Gly Leu Met 200 Ser Ala Gln Tyr Gly Gly Met Val Lys Arg Val Gln His Gly Phe Ala Ala Arg Asn Gly Leu Leu Gly Gly Leu Leu Ala His Gly Gly Tyr Glu Ala Met Lys Gly Val Leu Glu Arg Ser Tyr Gly Gly Phe Leu Lys Met Phe Thr Lys Gly Asn Gly Arg Glu Pro Pro Tyr Lys Glu Glu Glu Val Val Ala Gly Leu Gly Ser Phe Trp His Thr Phe Thr Ile Arg Ile Lys Leu Tyr Ala Cys Cys Gly Leu Val His Gly Pro Val Glu Ala Ile Glu Asn Leu Gln Gly Arg Tyr Pro Glu Leu Leu Asn Arg Ala Asn Leu Ser Asn Ile Arg His Val His Val Gln Leu Ser Thr Ala Ser Asn Ser His 325 330 Cys Gly Trp Ile Pro Glu Glu Arg Pro Ile Ser Ser Ile Ala Gly Gln 340 345 Met Ser Val Ala Tyr Ile Leu Ala Val Gln Leu Val Asp Gln Gln Cys Leu Leu Ser Gln Phe Ser Glu Phe Asp Asp Asn Leu Glu Arg Pro Glu 375 Val Trp Asp Leu Ala Arg Lys Val Thr Ser Ser Gln Ser Glu Glu Phe 395 390 Asp Gln Asp Gly Asn Cys Leu Ser Ala Gly Arg Val Arg Ile Glu Phe 405 410 Asn Asp Gly Ser Ser Ile Thr Glu Ser Val Glu Lys Pro Leu Gly Val Lys Glu Pro Met Pro Asn Glu Arg Ile Leu His Lys Tyr Arg Thr Leu 440 Ala Gly Ser Val Thr Asp Glu Ser Arg Val Lys Glu Ile Glu Asp Leu Val Leu Gly Leu Asp Arg Leu Thr Asp Ile Ser Pro Leu Leu Glu Leu Leu Asn Cys Pro Val Lys Ser Pro Leu Val <210> SEQ ID NO 13 <211> LENGTH: 861 <212> TYPE: DNA <213> ORGANISM: Aspergillus terreus <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(858) <400> SEQUENCE: 13 atg agt att caa cat ttc cgt gtc gcc ctt att ccc ttt ttt gcg gca 48 Met Ser Ile Gln His Phe Arg Val Ala Leu Ile Pro Phe Phe Ala Ala 5 ttt tgc ctt cct gtt ttt gct cac cca gaa acg ctg gtg aaa gta aaa

- 1	con	Τ.	11	าเเ	ea

Phe Cya Lew Pro Val Phe Ala His Pro Glu Thr Lew Val Lyo Val Lyo Val Lyo Za													con	tin	uea 			
Amp Ala Glu Amp Glu Leu Gly Ala Arg val Gly Tyy 11e Glu Leu Amp  Storm Ala Ser Gly Lyn 11e Leu Glu Ser Phe Arg Poo Glu Glu Arg Phe  Glu Amp Ser Gly Lyn 11e Leu Glu Ser Phe Arg Poo Glu Glu Arg Phe  So Glu Glu Arg Phe  Glu Glu Arg Phe  So Glu Glu Arg Ala Ula Ula Ula Ula Val Leu Leu Glu  Arg Ile Amp Ala Gly Glu Glu Glu Leu Gly Arg Arg Ile Hie Tyr Ser  So Glu Amn Amp Leu Val Glu Tyr Ser Pro Val Thr Glu Lyn His Leu Thr  100 Ala Glu Arg Glu Leu Cys Ser Ala Ala Ile Thr Met Ser  116 Amp Gly Her Thr Val Arg Glu Leu Cys Ser Ala Ala Ile Thr Met Ser  118 120  Sat age atg ace ga gae aga tta gt age gae gae gae gae gae gae gae gae gae	Phe	Cys	Leu		Val	Phe	Ala	His		Glu	Thr	Leu	Val	_	Val	ГÀа		
Leu Aan Ser Giy Lys 16 Leu Giu Ser Phe Arg Pro Giu Giu Arg Phe 50 60  cca atg atg ago act ttt aas gtt ctg cta tgt ggc gcg gta tta tcc Pro Net Mer Ser Thr Phe Lys Val Leu Leu Cys Gy Ala Val Leu Ger 65 6 The Net Ser Thr Phe Lys Val Leu Leu Cys Gy Ala Val Leu Ger 65 6 The Ser Thr Phe Lys Val Leu Leu Cys Gy Ala Val Leu Ger 65 6 The Ser Thr Phe Lys Val Leu Leu Cys Gy Ala Val Leu Ger 75 70 70 70 70 70 70 70 70 70 70 70 70 70			Glu					Āla					Ile				144	
Pro Net		Asn					Leu					Pro					192	
Arg lie Asp Ala Gly Gln Glu Gln Lew Gly Arg Arg lie His Tyr Ser 985  cag aat gac ttg gtt gag tac tca cca gtc aca gaa aag cat ctt acg Gln Ann Any Lew Val Glu Tyr Ser Pro Val Thr Glu Lyn His Lew Thr 100  gat ggc atg aca gta aga gaa tta tgc agt gct gcc ata acc atg agt Any Dinter Thr Val Arg Glu Lew Cyn Ser Ala Ala lie Thr Met Ser 115  gat aca cat gcg gcc aac tta ctt ctg aca acg atc gca gga ccg aag Any Any Thr Ala Ala Ann Lew Lew Lew Thr Thr II Gly Gly Pro Lyn 130  gag cta acc gct ttt ttg cac aac atg ggg gat cat gta act cgc ttg lu Lew Thr Ala Phe Lew His Ann Met Gly Any His Val Thr Arg Lew 145  gat cat acc gct tgg gaa ccg ga ctg at gas gcc at acca aca gac gac gag gat cat gta act cgc ttg gaa ccg gag cgg acc aga cag acg acg ac	Pro					Phe					Cys					Ser	240	
Gin Asn Asp Leu Val Glu Tyr Ser Pro Val Thr Glu Lys His Leu Thr 110   gat ggc atg aca gta aga gas tta tgc agt gct gcc ata acc atg agt   Asp Gly Met Thr Val Arg Glu Leu Cys Ser Ala Ala 11e Thr Met Ser   125   gat aac act gcg gcc asa tta ctt ct g aca acg atc gga gga ccg aag   Asp Asn Thr Ala Ala Asn Leu Leu Leu Thr Thr 11e Gly Gly Pro Lys   130   gag cta acc gct ttt ttg cac aac atg ggg gat cat gta gta gct gut gcg ctg gat cgt ggg ctg ttg gaa ccg gag ctg at gat gat gat gat gat ggt ggt ggg at cat gta acc ggt tgg gaa ccg gag ctg atg gat gat gat gat gat gat gat gat g	_		_	_	Gly					Gly	_	_			Tyr		288	
App Gly Met Thr Val Arg Glu Leu Cys Ser Ala Ala IIe Thr Met Ser 115 120 120 125 125 125 125 125 125 125 125 125 125	_		_	Leu	_				Pro	-		_	_	His		-	336	
Asp Asp Thr Ala Ala Asp Leu Leu Leu Thr Thr Ile Gly Gly Pro Lys 130  gag cta acc get ttt ttg cac aac atg ggg gat cat gta act cgc ctt Glu Leu Thr Ala Phe Leu His Asp Met Gly Asp His Val Thr Arg Leu 145  gag cta ggt tgg gaa ccg gag ctg aat gaa gac acc aca ac gac gag cgt Amp Arg Trp Glu Pro Glu Leu Asp Glu Ala lee Pro Asp Amp Glu Arg 175  gag cac acc acg atg cct gag atg ga atg ga acc aca acg gac gag cgt Amp Arg Trp Glu Pro Val Ala Met Ala Thr Thr Leu Arg Lys Leu Leu 180  180  act ggc gaa cta ctt act cta gct tcc cgg caa caa ta ata gac tgg Thr Gly Glu Leu Thr Leu Ala Ser Arg Gln Gln Leu Ile Asp Trp 195  atg gag ggc gaa aaa gtt gca gga cca ctt ctc cgg caa caa tta ata gac tgg atg gag gag ata aa gtt gca gga cca ctt ctc cgc tcg ccc tcc cgg 400  410  421  421  420  421  420  420			Met					Leu					Ile				384	
GIU Leu Thr Ala Phe Leu His Asn Met Oly Asp His Val Thr Arg Leu       145       160       170       170       175       175       28       24       28       29       28       28       24       24       24       24       24       24       24       24       24       24       24       24       28       28       22       22       22       22       22       22       22       22       2	_	Asn			_		Leu		_		_	Ile			_	_	432	
Asp Arg Trp Glu Pro Glu Leu Asn Glu Ala Ile Pro Asn Asp Glu Arg 175         Glu Arg 175         Glu Leu Asn Glu Ala Ile Pro Asn Asp Glu Arg 175         Glu Leu Leu Leu Ile Ala Ser Arg Gln Gln Gln Leu Ile Asp Trp 180         Glu Arg 175         Glu Leu Leu Leu Leu Leu Leu Leu Leu Leu Le	Glu			_		Leu			_		Asp		_		_	Leu	480	
Asp Thr Thr Net 180 Pro Val Ala Met Ala Thr Thr Leu Arg Lys Leu Leu 190  act ggc gaa cta ctt act cta gct tcc cgg caa caa tat ata ata gac tgg far first Gly Glu Leu Leu Thr Leu Ala Ser Arg Gln Gln Leu Ile Asp Trp 205  atg gag gcg gat aaa gtt gca gga cca ctt ctg cgc tcg gcc ctt ccg Met Glu Ala Asp Lys Val Ala Gly Pro Leu Leu Arg Ser Ala Leu Pro 210  gct ggc tgg ttt att gct gat aaa tct gga gcc ggt gag cgt ggg tct Ala Gly Trp Phe Ile Ala Asp Lys Ser Gly Ala Gly Glu Arg Gly Ser 235  cgc ggt atc att gca gca ctg ggg ca gat cag gat ggt ggg tct Ala Gly Ile Ile Ala Ala Leu Gly Pro Asp Gly Lys Pro Ser Arg Ile 255  gta gtt atc tat act act act act act act act a					Pro					Āla					Glu		528	
Thr Gly Glu Leu Leu Thr Leu Ala Ser Arg Gln Gln Leu 11e Asp Trp 205  atg gag gcg gat aaa gtt gca gga cca ctt ctg cgc tcg gcc ctt ccg 210  atg gag gcg gat aaa gtt gca gga cca ctt ctg cgc tcg gcc ctt ccg 210  gct ggc tgg ttt att gct gat aaa tct gga gcc ggt gag cgt ggg tct Ala Gly Trp Phe Ile Ala Asp Lys Ser Gly Ala Gly Glu Arg Gly Ser 225  cgc ggt atc att gca gca ctg ggg ca gt ggg cca gat ggt aag ccc tcc cgt atc Arg Gly Ile Ile Ala Ala Leu Gly Pro Asp Gly Lys Pro Ser Arg Ile 245  gta gtt atc tac acg acg ggg agt cag gca act atg gat gat acg glu Arg Gly Ala Gly Arg Gly 260  gta gtt atc tac acg acg ggg agt cag gca act atg gat gat gat gat gat acg acg act atg gat acg acg acg act acg gat gat cag gca act atg gat gat acg				Met					Āla					Lys			576	
Met         Glu Ala Asp 210         Lys         Val Ala Gly Pro Leu Leu Arg 220         Ser Ala Leu Pro 220           gct         ggc tgg ttt att gct ggt ala Gly Trp Phe Ile Ala Asp 230         ggt ggg gcc ggt atc att gca gca ctg ggg cca gg ggg ggg ggg ggg ggg ggg ggg			Glu					Āla					Leu		_		624	
Ala Gly Trp Phe Ile Ala Asp Lys Ser Gly Ala Gly Glu Arg Gly Ser 235  cgc ggt atc att gca gca ctg ggg cca gat ggt aag ccc tcc cgt atc Arg Gly Ile IIe Ala Ala Leu Gly Pro Asp Gly Lys Pro Ser Arg Ile 245  gta gtt atc tac acg acg ggg agt cag gca act atg gat gaa cga act Ala Glu Arg Asp 250  gta gtt atc tac acg acg ggg agt cag gca act atg gat gaa cga act Ala Thr Met Asp Glu Arg Asn 265  aga cag atc gct gag ata ggt gcc tca ctg att aag cat tgg taa Arg Gln Ile Ala Glu Ile Gly Ala Ser Leu Ile Lys His Trp 275  285 <pre> </pre> <a href="#"></a>	_	Glu		_		_	Āla				_	Arg	_	_		_	672	
Arg Gly Ile Ile Ala Ala Leu Gly Pro Asp Gly Lys Pro Ser Arg Ile 245  gta gtt atc tac acg acg ggg agt cag gca act atg gat gas cag aat Val Val Ile Tyr Thr Thr Gly Ser Gln Ala Thr Met Asp Glu Arg Asn 265  aga cag atc gct gag ata ggt gcc tca ctg att aag cat tgg taa Arg Gln Ile Ala Glu Ile Gly Ala Ser Leu Ile Lys His Trp 275  285  <210 > SEQ ID NO 14 <211 > LENGTH: 286 <212 > TYPE: PRT <213 > ORGANISM: Aspergillus terreus	Ala 225	Gly	Trp	Phe	Ile	Ala 230	Asp	Lys	Ser	Gly	Ala 235	Gly	Glu	Arg	Gly	Ser 240		
Val Val Ile Tyr Thr Thr Gly Ser Gln Ala Thr Met Asp Glu Arg Asn 260 270  aga cag atc gct gag ata ggt gcc tca ctg att aag cat tgg taa 861  Arg Gln Ile Ala Glu Ile Gly Ala Ser Leu Ile Lys His Trp 275 280 285  <210> SEQ ID NO 14  <211> LENGTH: 286  <212> TYPE: PRT  <213> ORGANISM: Aspergillus terreus	Arg	Gly	Ile	Ile	Ala 245	Ala	Leu	Gly	Pro	Asp 250	Gly	Lys	Pro	Ser	Arg 255	Ile		
Arg Gln Ile Ala Glu Ile Gly Ala Ser Leu Ile Lys His Trp 275 280 285  <210> SEQ ID NO 14 <211> LENGTH: 286 <212> TYPE: PRT <213> ORGANISM: Aspergillus terreus	Val	Val	Ile	Tyr 260	Thr	Thr	Gly	Ser	Gln 265	Ala	Thr	Met	Asp	Glu 270	Arg			
<211> LENGTH: 286 <212> TYPE: PRT <213> ORGANISM: Aspergillus terreus			Ile					Āla					His		taa		861	
	<21 <21	1> LI 2> T	ENGTI YPE :	H: 2: PRT	86	ergi:	llus	ter	reus									
					_	-												

Met Ser Ile Gln His Phe Arg Val Ala Leu Ile Pro Phe Phe Ala Ala 1 5 10 15

Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr Leu Val Lys Val Lys

-continued

			20					25					30		
Asp	Ala	Glu 35	Asp	Gln	Leu	Gly	Ala 40	Arg	Val	Gly	Tyr	Ile 45	Glu	Leu	Asp
Leu	Asn 50	Ser	Gly	Lys	Ile	Leu 55	Glu	Ser	Phe	Arg	Pro 60	Glu	Glu	Arg	Phe
Pro 65	Met	Met	Ser	Thr	Phe 70	ГÀз	Val	Leu	Leu	Сув 75	Gly	Ala	Val	Leu	Ser 80
Arg	Ile	Asp	Ala	Gly 85	Gln	Glu	Gln	Leu	Gly 90	Arg	Arg	Ile	His	Tyr 95	Ser
Gln	Asn	Asp	Leu 100	Val	Glu	Tyr	Ser	Pro 105	Val	Thr	Glu	Lys	His 110	Leu	Thr
Asp	Gly	Met 115	Thr	Val	Arg	Glu	Leu 120	CÀa	Ser	Ala	Ala	Ile 125	Thr	Met	Ser
Asp	Asn 130	Thr	Ala	Ala	Asn	Leu 135	Leu	Leu	Thr	Thr	Ile 140	Gly	Gly	Pro	Lys
Glu 145	Leu	Thr	Ala	Phe	Leu 150	His	Asn	Met	Gly	Asp 155	His	Val	Thr	Arg	Leu 160
Asp	Arg	Trp	Glu	Pro 165	Glu	Leu	Asn	Glu	Ala 170	Ile	Pro	Asn	Asp	Glu 175	Arg
Asp	Thr	Thr	Met 180	Pro	Val	Ala	Met	Ala 185	Thr	Thr	Leu	Arg	Lys 190	Leu	Leu
Thr	Gly	Glu 195	Leu	Leu	Thr	Leu	Ala 200	Ser	Arg	Gln	Gln	Leu 205	Ile	Asp	Trp
Met	Glu 210	Ala	Asp	Lys	Val	Ala 215	Gly	Pro	Leu	Leu	Arg 220	Ser	Ala	Leu	Pro
Ala 225	Gly	Trp	Phe	Ile	Ala 230	Asp	ГÀз	Ser	Gly	Ala 235	Gly	Glu	Arg	Gly	Ser 240
Arg	Gly	Ile	Ile	Ala 245	Ala	Leu	Gly	Pro	Asp 250	Gly	ГÀз	Pro	Ser	Arg 255	Ile
Val	Val	Ile	Tyr 260	Thr	Thr	Gly	Ser	Gln 265	Ala	Thr	Met	Asp	Glu 270	Arg	Asn
Arg	Gln	Ile 275	Ala	Glu	Ile	Gly	Ala 280	Ser	Leu	Ile	Lys	His 285	Trp		

The invention claimed is:

- 1. Recombinant host cells that have been modified to improve production of itaconate,
  - said cells having been modified only to contain a nucleic acid that encodes protein wherein said encoded protein consists of the amino acid sequence of an itaconate transporter protein that transports itaconate acids from the cytosol to the extracellular medium; and
  - optionally nucleic acid that encodes protein wherein said encoded protein consists of the amino acid sequence of the enzyme cis aconic acid decarboxylase (CAD), and optionally nucleic acid that encodes protein wherein 55 said encoded protein consists of the amino acid sequence of a protein capable of transporting di/tricarboxylic acids from the mitochondrion,
  - wherein the itaconate transporter protein has the amino acid sequence of SEQ ID NO:3 or an amino acid 60 sequence at least 95% identical thereto or SEQ ID NO:6, wherein the host cells are heterologous to said nucleic acid.
- 2. The host cells of claim 1, wherein nucleic acid encodes a protein having SEQ ID NO:3 or SEQ ID NO:6.
- 3. The host cells of claim 1, which are cells of a citrate producing micro-organism.

- 4. The host cells of claim 3, wherein the citrate producing microorganism is A. terreus, A. niger, A. itaconicus, A. nidulans, A. oryzae, A. fumigates, Yarrowia lipolytica, Ustilago zeae, Candida sp.,Rhodotorula sp., Pseudozyma antarctica, E. coli, or Saccharomyces cerevisiae.
- 5. The host cells of claim 4, wherein the citrate producing microorganism is *A. terreus* or *A. niger*.
- **6**. The host cells of claim **1**, which are of a lovastatin producing organism.
- 7. The host cells of claim 6, wherein the lovastatin producing microorganism is *Monascus* spp., *Penicillium* spp., *Hypomyces* spp., *Doratomyces* spp., *Phoma* spp., *Eupenicillium* spp., *Gymnoascus* spp., *Pichia labacensis*, *Candida cariosilognicola*, *Paecilomyces varioti*, *Scopulariopsis brevicaulis* or *Trichoderma* spp.
- 8. The host cells of claim 1, which are also modified with a nucleic acid that encodes protein wherein said encoded protein consists of the amino acid sequence of the enzyme cis aconic acid decarboxylase (CAD), wherein said nucleic acid encoding the enzyme CAD comprises a nucleotide sequence which encodes the amino acid sequence of SEQ ID NO:12.
- 9. The host cells of claim 1, which are also modified with a nucleic acid that encodes protein wherein said encoded pro-

54

tein consists of the amino acid sequence of a protein capable of transporting di/tricarboxylic acids from the mitochondrion, wherein the nucleotide sequence encodes a protein of the amino acid sequence SEQ ID NO:14.

- 10. The host cells of claim 1, wherein the nucleic acid 5 encoding itaconate transporter comprises SEQ ID NO:2 or a nucleotide sequence at least 95% identical thereto or SEQ ID NO:5.
- 11. The host cells of claim 10, wherein the nucleic acid encoding itaconate transporter comprises SEQ ID NO:2 or  $^{10}$  SEQ ID NO:5.

\* \* \* \* \*